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Abstract 
Background and objectives: Cervical cancer is a major cause of cancer-related deaths in many 
developing countries yet it is a preventable and treatable in early disease. Recent research has 
seen increasing morbidity and mortality due to cancer of the cervix attributed to the advent of 
the human immunodeficiency virus (HIV) epidemic worldwide. Papanicolaou smears (Pap 
smears) to detect cervical abnormalities are currently the best known form of early detection 
and prevention of invasive cervical cancer (ICC).  
Knowledge and awareness about cervical cancer and associated risk factors, and cervical 
screening is very important in determining appropriate health seeking behaviours with the aim 
to reduce morbidity and mortality. This study examines awareness, perceived risk and practices 
related to cervical cancer screening among HIV-positive women in an urban HIV clinic in 
Johannesburg, South Africa. This will be useful in making recommendations with regards to 
designing and planning of screening programmes, and addressing cervical cancer education and 
awareness. 
Materials and methods: This study analysed secondary data collected from an ongoing 
cervical cancer study undertaken by Right to Care in partnership with the Clinical HIV Research 
Unit (CHRU) among HIV-positive adult (18 years and older), female patients enrolled in the 
Themba Lethu Clinic HIV care and treatment programme in Johannesburg, South Africa from 
November 2009 to December 2012. Clinical data for all respondents was extracted from 
TherapyEdge-HIVTM, the electronic medical database system used for patient management at 
the facility.  
Descriptive statistics were used to summarise baseline characteristics. Models using logistic 
regression were developed to estimate odds ratios (OR) to further identify baseline socio-
demographic factors and clinical characteristics associated with behaviours studied (awareness, 
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perceived risk and practice related to cervical cancer and Pap smear testing) and to identify the 
association between these factors and the prevalence and severity of cervical disease. 
Awareness of the Pap smear test and the human papillomavirus (HPV) was assessed based on 
whether the women report knowing what a Pap smear test is, and whether they have ever heard 
about HPV. Perceived risk about getting cervical cancer was assessed based on how worried 
the study participants were about getting cervical cancer. Previous Pap screening practice was 
assessed using reported screening history of the study participants. In addition to this, a sub-
analysis was conducted to see how these responses compare to 1) the recommended practice 
according to the South African national cervical cancer screening guidelines based on the age 
of participants, and 2) the latest HIV treatment guidelines based on year of HIV diagnosis. 
Analysis of attrition of study participants at 12 months of study participation was conducted 
using different time to event analysis techniques including Kaplan Meier, Log-rank test and 
Cox proportional hazards model. Cox proportional hazards models were fitted to investigate 
associations between baseline covariate and attrition. 
A sub-analysis was also carried out using descriptive statistics and chi-square tests to compare 
the cohort of patients that were included in the study (the VICAR1 cohort) and the rest of the 
larger Themba Lethu Clinic (TLC) population that was not included in the study to see if there 
were any significant differences noted between the two groups. In addition, a sensitivity 
analysis of the of 12 month follow up study visit was conducted using descriptive statistics and 
chi-square tests to determine if there were any significant differences between study participants 
that came for their 12 month study visit and those that did not come for their 12 month study 
visit. 
Results: Eight hundred and fifty seven (71.30%) participants reported to be aware of Pap smear 
screening, with only 18.15% reporting to be aware of HPV. Of the 1192 participant who had 
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data to ascertain perceived risk regarding cervical cancer disease, 662 (55.54%) of the women 
were very worried, 250 (20.97%) were somewhat worried, 280 (23.49%) were not worried 
about getting cervical cancer. A total of 381 (36.46%) women had adequate practice according 
to the national cervical cancer screening guidelines. While 304 (28.57%) had adequate practice 
according to the national HIV treatment guidelines. 
Factors associated with Pap smear screening awareness were being in the 50+ age group 
(aOR=4.70, 95% CI 1.63-13.55) as compared to the 18-29 age group, being of non-South 
African nationality (aOR=0.41, 95% CI 0.20-0.83), having a grade 10 to matric level education 
(aOR=2.12, 95%CI 1.28-3.52), and a tertiary level education (aOR=2.62, 95%CI 1.07-6.41) as 
compared to having a less than a grade 10 level education. None of the factors assessed were 
found to be significantly associated with awareness regarding HPV.  
Factors associated with perceived risk regarding cervical cancer disease were having a tertiary 
education (aOR=3.74, 95%CI 1.13-12.38) as compared to having less than a grade 10 level, 
taking snuff (aOR=0.55, 95%CI 0.33-0.92) and drinking alcohol (aOR=2.53, 95% CI 1.24-
5.17). Being in the 30-39 age group (aOR=12.23, 95%CI 4.00-37.35) as compared to being in 
18-29 age group, cohabiting with a partner (aOR=0.36, 95%CI 0.17-0.75) as compared to being 
single, being self-employed (aOR=2.95, 95%CI 0.82-10.66) as compared to those in full time 
employment, and being initiated on highly active antiretroviral therapy (aOR=0.17, 95%CI 
0.06-0.55) were associated with Pap smear screening practices according to the national cervical 
cancer guidelines. None of the factors proved to be significantly associated with the practice 
according to the national HIV treatment guidelines, this is mainly because the HIV treatment 
guidelines have stricter screening requirements for HIV positive women.  
Those that had  a moderate to severe baseline study Pap smear at enrolment into the study were 
92% less likely  to have disease progression at their 12 month Pap smear screening (aOR=0.08, 
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95%CI 0.05-0.13) compared to those that had a negative baseline Pap smear at study enrolment. 
This is mostly because they would have had a treatment intervention based on their baseline 
study Pap screening result therefore they would mostly likely not have disease progression at a 
follow up screening. 
Only seven women enrolled in the study died of non-cervical cancer related causes during the 
study period. In the analysis on all-cause attrition (deceased or lost to follow up) those that are 
initiated on highly active antiretroviral therapy were 92% less likely to be deceased or lost to 
follow up than those that were not initiated on highly active antiretroviral therapy (aOR=0.08, 
95% CI 0.05-0.13). The global test for the overall model showed that the proportional hazard 
assumption had not been violated, p=0.684. 
Conclusions: Results for our study showed high levels of Pap smear screening awareness 
amongst the study participants. However, low levels of Pap screening uptake was observed for 
study participants. These results and results shown in previous studies show that awareness is 
only the first hurdle in the challenges related to cervical cancer prevention and treatment. 
Adequate practice is the factor that will have the most positive influence on the disease 
morbidity and mortality. Rates of screening practices have been found to be worse in 
populations with less than 70% Pap smear screening awareness.  
Findings from this study and similar findings from other studies highlight that more research 
needs to be done into effective health education programmes to address the gaps in adequate 
screening practice. These efforts should not only target the clients but also the health providers 
as they also have an important role to play in improving awareness, knowledge and practices 
related to cervical cancer and Pap smear screening amongst their clients. 
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CHAPTER 1: Introduction 
1.1. Background 
Cervical cancer is considered to be a major public health concern in Southern Africa and all 
over the world.  It is said to be the second most common cancer to affect women globally, with 
close to 530 000 new cases and 270 000 deaths from the disease in 2012 (1). Over 85% of the 
cervical cancer related deaths are from less developed regions (1). It is a major cause of cancer-
related deaths in women in many developing countries yet it is a preventable and treatable 
disease. 
Recent studies have shown that the human papillomavirus (HPV) plays an important role in the 
development of pre-cancerous lesions and their progression into cancer (2, 3, 4). In addition 
the development of the disease has been found to also be associated with many other factors, 
including an early sexual debut, multiple sexual partners, smoking and extended use of oral 
contraceptives (5).   
Human immunodeficiency virus (HIV) infection also represents a tremendous health burden 
worldwide. The Joint United Nations Programme on HIV/ acquired immunodeficiency 
syndrome (AIDS), (UNAIDS), estimated that in 2012, an estimated 35.3 million people were 
HIV infected; 25 million of these live in sub-Saharan Africa with over 60% of these being 
women (6). Recent research has seen increasing morbidity and mortality due to cancer of the 
cervix attributed to the advent of the HIV epidemic worldwide. The World Health Organisation 
(WHO) now regards invasive cervical cancer (ICC) as an AIDS-defining illness (1, 7, 8, 9). 
The association between HIV and ICC is complex, with several studies now demonstrating an 
increased risk of pre-invasive cervical lesions among HIV-infected women (3, 4, 10). HIV-
infected women with more advanced immune-suppression (CD4 count < 200 cells/µL) seem 
to be particularly vulnerable to infection with persistence of the high-risk HPV types that can 
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lead to cancer (10).  The introduction of highly active antiretroviral therapy (HAART) in the 
fight against HIV has added new complexities in the fight against both diseases. Previous 
studies have shown that there is a greater lifetime risk of cervical dysplasia among HIV positive 
women on HAART because of the increased life expectancy as a result of HAART (7). 
However, some studies have shown initiation of HIV positive women on HAART may reduce 
the prevalence and progression of cervical pre-cancerous lesions (7, 10).  
Papanicolaou smears (Pap smears) to detect cervical abnormalities are currently the best 
known form of early detection and prevention of ICC (11, 13, 14). It remains the most 
effective means of prevention of both the incidence of and mortality from ICC (11). ICC 
progresses slowly, often taking many years to develop therefore early detection of abnormal 
cells means better treatment options and a better prognosis (11). 
Knowledge and awareness about cervical cancer and associated risk factors, and cervical 
screening is very important in determining appropriate health seeking behaviours with the aim 
to reduce morbidity and mortality (10). This study examines awareness, perceived risk and 
practices related to cervical cancer screening among HIV-positive women in an urban HIV 
clinic in Johannesburg, South Africa. This will be useful in making recommendations with 
regards to designing and planning screening programmes, and addressing cervical cancer 
education and awareness. 
1.2. Problem statement 
Cervical cancer is a disease that affects the tissues of the cervix (the organ connecting the uterus 
and vagina) in the female reproductive system (12). It is a typically slow-growing cancer that 
may not present symptoms until the very late stages when it has advanced and spread, and may 
be difficult to treat; resulting in low cure rates and high fatality rates (12). 
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Pap smear screening is a microscopic examination of cells taken from the cervix. A Pap smear 
can detect changes of cells caused by infections such as HPV which is the underlying cause of 
cervical cancer (12). The natural history of ICC shows good potential for prevention and cure 
as it slowly progresses through stages of pre-cancerous intraepithelial lesions before developing 
into an invasive form (2, 11). This allows for early detection which is pivotal as a prevention 
mechanism to improve the prognosis and increase the possibility of complete eradication using 
available treatment interventions (11).  
Cervical cancer begins with the development of pre-cancerous, benign lesions in the cervix. 
According to WHO classification, the first stage of development is mild dysplasia, which can 
then progress to becoming moderate dysplasia, severe dysplasia, and then carcinoma in situ 
(CIS) or ICC (2, 12).  
There are two systems of classification in reporting cervical screening results, one is based on 
a biopsy (histology section) of the cervix and the other is based on a Pap smear (also termed 
cytology-based Pap smear). Cell abnormalities that are seen on a biopsy of the cervix use the 
term cervical intraepithelial neoplasia (CIN), and according to this system mild to moderate 
dysplasia are classified as CIN1, intermediate dysplasia as CIN2, and severe dysplasia and 
carcinoma in situ are together classified as CIN3 (2, 12).  
Cell abnormalities that are seen on a Pap smear are described using the Bethesda system that 
uses the terms squamous intraepithelial lesion (SIL) or atypical squamous cells (ASC).  The 
Bethesda system simplifies CIN system further by classifying CIN1 as Low Grade Squamous 
Intraepithelial Lesion (LSIL) or atypical squamous cells of undetermined significance 
(ASCUS), and both CIN2 and CIN3 as High Grade Squamous Intraepithelial Lesion (HSIL) or 
atypical squamous cells where a high-grade squamous intraepithelial lesion cannot be excluded 
(ASC-H) (2, 12). 
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High income countries have seen a reduction of 70% in the burden of cervical cancer screening 
as a result of the introduction of routine Pap smear testing in organised screening programmes 
(15, 16). In 2000, the South African government put in place a national cervical screening 
guideline which used the early detection and treatment approach for prevention of the disease. 
The guidelines recommend three Pap smears in a lifetime at 10 year intervals, at 30, 40 and 50 
years of age in public sector health facilities (17). However, cervical cancer has been found to 
progress earlier to ICC in women whose immune system has been compromised by HIV (18).  
Therefore it is very important to integrate cervical cancer screening with HIV/AIDS prevention, 
care and treatment services to ensure that Pap smear testing services are available in this setting 
and are administered according to the latest guidelines (19).  
The guidelines for the management of HIV/AIDS released by the South African Department of 
Health in 2010, with the latest edition released in 2013, stated that all HIV-positive women 
need cervical cancer screening on diagnosis of HIV, and if this test is negative then subsequent 
screening every three years, irrespective of HAART status (18). If the results of a Pap smear is 
abnormal the guidelines recommend a repeat Pap smear according to the results of the first Pap 
smear as follows (18): 
- ASCUS - repeat in one year and if still ASCUS, refer for baseline colposcopy. 
- LSIL - repeat in one year and if still LSIL, refer for baseline colposcopy 
- HSIL/ASC-H - refer for colposcopy 
- Carcinoma in situ - refer immediately 
Even so, introducing a national prevention strategy for cervical cancer not only requires the 
provision of the most appropriate, and cost effective screening service, but should also ensure 
that women who need the service, utilize and benefit from the service (20). Previous studies 
have shown that health promotion and advocacy around cervical cancer and Pap screening are 
very important in improving coverage of screening services. A comparative study among 
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women from Japan and Brazil showed that knowing the goal of the Pap smear test influenced 
women to take the test, which in turn resulted in a greater, more proactive, demand for the test 
(21).  
Lack of knowledge and awareness of cervical cancer and cervical screening and treatment of 
abnormal Pap smears is seen as a major barrier to preventing cervical cancer. This is in addition 
to a number of other factors that include low education levels, poverty, religious/cultural beliefs 
and limited health resources (22). Innovative strategies to increase awareness of cervical cancer 
and the importance of screening as a preventive measure are needed, especially in high risk 
population groups such as HIV-positive women (14, 23). 
According to a WHO report on comprehensive cervical cancer control, health education and 
promotion should be an integral part of any national cervical cancer control programme (12). 
It should incorporate an awareness component, behaviour change communication, and 
counselling (12). The challenge is that currently little is known about knowledge and awareness 
and screening practices among HIV positive women in Southern Africa. In addition to this, 
cervical cancer disease and it’s prevention does not get the same amount of recognition and 
media attention as the other more recognized diseases in the region; Malaria, HIV, and TB and 
therefore often loses out in the competition for priority in resources in the already overburdened 
resource-poor health systems in developing countries including those in Southern Africa.  
1.3. Justification for the study 
There is limited data on health-seeking behaviour of HIV positive women for conditions other 
than their HIV infection. Getting a better understanding of this behaviour will assist in 
formulating better strategies to improve uptake of services including critical prevention 
services crucial to this group such as cervical cancer screening. 
In order for a national approach to cervical cancer screening to work, women need to be aware 
of cervical cancer and associated risk factors, as well as the screening and treatment services 
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available to them. If patients are not aware of the disease and associated risks, they will not 
seek timely screening or treatment services and therefore are at higher risk of disease 
progression and poor prognosis (22).  
ICC progresses slowly, often taking many years to develop. Therefore cervical cancer screening 
can help find cancer or precancerous changes at an early stage, and when abnormal tissue/ pre-
cancerous lesions are caught in the early stages, before they become invasive they are easier to 
treat (12, 24). There are a number of treatment options for pre-cancerous lesions (12, 24): 
- Laser surgery uses a laser beam to destroy abnormal cells. 
- Cryosurgery destroys cancerous and pre-cancerous lesions by freezing them. 
- Loop electrosurgical excision procedure (LEEP) uses a thin wire loop (through 
which an electrical current is passed) to cut away an area of abnormal cells from 
the cervix.  
- Conization surgically removes a cone-shaped piece of tissue from the cervix. 
These procedures are not as complicated, invasive and as costly as the interventions employed 
when the pre-cancerous lesions have progressed to a more invasive form (12, 24). 
There is a variety of treatment options for patients with ICC, of which the most common include 
surgery, chemotherapy and radiation. Surgery is in the form of a hysterectomy and it involves 
the removal of the uterus; and chemotherapy uses drugs to stop growth of the cancerous cells 
(24). Radiation therapy uses high energy- X-rays or other types of radiation to kill cells or keep 
them from growing. These procedures are not only complicated and invasive with a variety of 
side-effects, but they are costly and require significant resources, highly skilled health staff, 
and infrastructure (24). The World Bank study on cervical cancer prevention showed that 
screening for the early detection and treatment of abnormal cervical tissue was far cheaper than 
hospital-based treatment of advanced cancer (25). Therefore early detection of abnormal cells 
means better treatment options and a better prognosis. 
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This study examines awareness, perceived risk and practices related to cervical cancer 
screening among HIV-positive women in an urban HIV clinic in Johannesburg, South Africa. 
The study further assessed the association between socio-demographic characteristics and 
awareness, perceived risk and practices related to cervical cancer screening. The study also 
assessed the relationship between awareness, perceived risk and practices related to cervical 
cancer and the outcome of the most recent Pap smear screening. This will be useful in making 
recommendations with regards to addressing cervical cancer education and awareness when 
designing, planning and implementing screening programmes. 
1.4. Literature review 
Cervical cancer is largely a preventable and curable disease but despite this it is still a major 
burden on women’s public health worldwide (26). Data obtained from the IARC (International 
Agency for research on Cancer) - GLOBOCAN 2012 database, shows that cervical cancer was 
responsible for close to 270 000 deaths in 2012, over 85% of which occurred in developing 
countries with 57 000 occurring in Africa (26, 27). 
The HIV/AIDS epidemic continues to have widespread detrimental effects on people all over 
the world. UNAIDS reported an increase in people living with HIV worldwide in its annual 
AIDS epidemic update (6). They reported an estimated increase from 8 million in 1990 to 33 
million by end of 2008 of which 67% live in sub-Saharan Africa, with South Africa reported 
to be one of the country’s worst affected by the epidemic (6).   
 
Research has shown that there is a link between cervical cancer and HIV/AIDS infection. 
Generally HIV-infected women are reported to have a greater persistence of HPV infection 
with higher prevalence rates of LSIL and HSIL, more rapid progression rates and higher 
recurrence rates following treatment interventions (7, 8, 10, 16, 28, 29, 30). Gaym et al. reported 
an association between HIV sero-positivity and abnormal Pap smear results in their study 
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among young HIV-positive women in rural KwaZulu Natal, South Africa (16). Earlier studies 
in Rwanda and Kenya reported a prevalence of squamous intra-epithelial lesions (SIL) among 
HIV-positive women ranging from 31-63% (31, 32). A study by Theiler et al. using HIV 
Epidemiology Research Study (HERS) data found higher rates of re-activation of latent HPV 
infections among HIV-infected women than in un-infected women. Low CD4 count and age 
younger than 35 years were found to be significant factors of re-infection amongst the HIV-
infected women in the HERS study (33).  
In the midst of an ever increasing burden of HIV especially among young women, researchers 
have also observed that HIV-positive women presenting with cervical cancer are significantly 
younger than their HIV-negative counterparts presenting with the same disease (16, 28). Some 
researchers suggests expansion of the overall resources allocated for the cervical cancer 
screening programme to be able to detect cervical cancer among this subgroup of women (16). 
The current national screening programmes in South Africa and other developing countries 
may overlook this subgroup of women until they are older, but by then whatever abnormalities 
they might have had when they were younger would have progressed further into higher grade 
abnormalities (16). This emphasizes the importance of integrating Pap screening services and 
HIV services so that this subgroup of women can be identified earlier and receive the necessary 
treatment (34). 
Cervical cancer incidence and mortality rates have declined substantially in the developed 
world following the introduction of screening programmes. Screening programmes in Africa, 
are however, often emergent or non-existent (15). Memiah et al. found that only a mere 5% of 
women undergo cervical cancer screening in developing countries compared to a notably 
contrasting 40-50% in the developed world (10, 35). Previous studies have identified the lack 
of regular Pap smears as the single greatest risk factor for a poor outcome in women who 
develop cervical cancer (36). A study in Brazil showed an increased risk of ICC among women 
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who have never had a Pap test. In those women who had the test before, the risk increased 
proportionally to the amount of time elapsed since the last test (37). 
Lack of knowledge and awareness of cervical cancer and cervical screening has been shown to 
be one of the significant factors hampering the uptake of cervical screening services in the 
developing world (23). Findings from previous studies highlighted the importance of providing 
accurate information about cervical cancer and the purpose of Pap smear screening in order for 
screening programmes to be effective (8, 13). The prevalence of ever having a Pap smear 
among college students in a Ghana university was 12%, with only 7.9% of the respondents 
knowing about the link between HPV and cervical cancer (22). A patient’s medical practitioner 
was identified as the main source of information about the disease and the test, and influenced 
whether the patient took the test or not (13, 20, 37).  
Akinyemiju et al. also found low levels of screening history in a study reviewing health care 
access and cervical cancer screening by analysing data from the South African World Health 
Survey (WHS) (38). This study also found that availability of physicians was an important 
predictor of screening uptake (38). A concerning finding for low resource settings where 
increasing number of physicians is not a feasible option (38). Instead in these settings 
recommended strategies to increasing availability of the service include training nurses and 
other lower cadres of staff, and where possible to use screening methodologies not requiring 
complex pathology and laboratory infrastructure (39). 
The Health Belief Model postulate that people will engage in health seeking behaviour if they 
perceive benefits to themselves accruing from that behaviour (40).Various health behaviour 
theories suggest that screening utilisation and information seeking behaviour are mediated by 
perception of risk, attitude and knowledge, social influence and self-efficacy (40). Several 
studies have highlighted the significance of perceived risk for cervical cancer as an important 
factor that influences screening behaviour (41). A study in Kenya on the perceptions of risk 
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and barriers to cervical cancer screening found that 35% of participants did not think they were 
at risk of cervical cancer and felt no need to screen for the condition (41). In the same study the 
fear of abnormal results was highlighted as one of the barriers to women going for cervical 
screening; some of the women had a fatalistic view of cervical cancer screening where 
diagnosis of any abnormalities was equated with certain death (41, 42). This was due mostly to 
lack of knowledge and awareness about the disease.  
Stark et al. conducted a retrospective case-series study of cancer patients and cancer survivors 
and results showed little HPV knowledge, with only 19% of the participants accurately 
identifying HPV as the primary risk factor for cervical cancer (43). A disturbing result as one 
would expect that diagnosed patients who have undergone treatment would have had several 
opportunities to interact with the health practitioner and request/receive information or 
education about the disease.  
A cross-sectional study relating to cervical cancer and Pap screening among HIV patients was 
done in Italy where intravenous drug use was cited as the main mode of HIV transmission in 
the population. Again, as with other studies among non-HIV patients, the level of schooling 
was identified as a significant risk factor to having knowledge about the disease and the test. In 
addition, the study also showed that the area of birth was found to significantly impact on 
knowledge about the disease and the test (44).   
There have been limited studies assessing awareness, perceived risk and practices among HIV-
positive patients conducted in the South African context. Many of the studies conducted to 
assess knowledge, awareness, attitude, beliefs, perceived risk or screening practices relating to 
cervical cancer and screening were not done amongst HIV positive women or data on study 
participant’s HIV status was not collected. In addition, many of the studies involving cervical 
cancer and HIV positive women in Southern Africa mostly focus mostly on clinical aspects 
related to the both disease as opposed to behavioural aspects such as the women’s cervical 
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cancer screening practice (8, 9, 10, 16, 29). Screening behaviour and general health seeking 
behaviour related to prevention services is not widely studied amongst HIV positive women in 
South Africa (10, 38). Especially in the context of the comorbidities that present themselves to 
this subgroup of women as a result of their previous immunosuppression and their increased 
life expectancy as a result of being initiated on HAART. Therefore this study aims to examine 
the awareness, perceived risk and practices related to cervical cancer and Pap smear screening 
among HIV-positive women in an urban HIV clinic in Johannesburg, South Africa and identify 
factors associated with these and the impact on the prevalence and severity of the disease.   
1.5. Study objectives: 
1.5.1. Main objective 
To assess the awareness, perceived risk and practices related to cervical cancer and Pap 
screening among HIV-positive women in an urban HIV clinic in Johannesburg, South Africa. 
1.5.2. Specific objectives 
1. To assess awareness, perceived risk and practices related to Pap smear testing among 
women enrolled in an HIV care and treatment programme in a Johannesburg public 
sector clinic between November 2009 and December 2012. 
2. To assess the socio-demographic characteristics and clinical characteristics at HAART 
treatment initiation that may be associated with awareness, perceived risk and practices 
related to cervical cancer and Pap smear testing. 
3. To assess the association of awareness, perceived risk and practices related to Pap smear 
testing and the prevalence and severity of cervical disease using the outcome of the 
most recent Pap smear test. 
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4. To assess mortality and outcomes related to morbidity at 12 months follow-up of 
patients enrolled in the cervical cancer study in relation to their awareness, perceived 
risk and practices related to cervical cancer and Pap smear testing. 
CHAPTER 2: Materials and methods 
2.1. Study design 
In April 2005, the non-governmental organization (NGO) Right to Care in partnership with the 
South African (SA) government established a cervical cancer screening and treatment centre 
alongside the HIV care, management and treatment facility in the Themba Lethu Clinic, 
Johannesburg, South Africa. The clinic has taken the lead in offering cervical screening for 
HIV-positive patients presenting with cervical disease (1).  
This study made use of secondary data collected from an ongoing Cervical Cancer study 
undertaken by Right to Care in partnership with the Clinical HIV Research Unit (CHRU) 
among HIV-positive adult females enrolled in the Themba Lethu Clinic HIV care and treatment 
programme in Johannesburg, South Africa. This primary study is a longitudinal study that aims 
to describe the patient population that is currently receiving cervical cancer screening at the 
Themba Lethu Clinic through the Validation of Implementation of Cervical Cancer Screening 
Applications in HIV-seropositive Women (VICAR 1) protocol, and their treatment outcomes 
through Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV- 
Seropositive Women (VICAR 2) protocol. Enrolment for VICAR 1 and VICAR 2 began in 
November 2009 and February 2010 respectively and is ongoing. 
2.2. Study population 
The study population comprised of a total of 1202 adult (≥18 years of age), HIV-positive female 
patients enrolled in the HIV Care and Treatment programme at Themba Lethu Clinic in 
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Johannesburg, South Africa, participating  in cervical cancer study (VICAR 1 and VICAR 2) 
from November 2009 to December 2012. 
2.3. Inclusion and exclusion criteria 
Eligibility 
i. HIV-positive females 
ii. Between and including women of 18-65 years of age 
iii. Eligible to participate in the cervical cancer study (VICAR 1 and VICAR 2) and 
signed written informed consent 
Exclusion criteria 
i. <18 years of age 
ii. Pregnant 
iii. Did not meet the eligibility criteria for VICAR 1 study 
iv. Did not sign consent 
2.4. Sample size  
The study made use of use of secondary data collected from the cervical cancer study 
(VICAR 1 and VICAR 2). The sample size for the primary study was estimated at 1200. Our 
study made use of all data collected as at the end of December 2012 which consisted of all 
1202 study participants.  
2.5. Measurement and data sources 
In the primary study participants answered an interviewer-administered structured 
questionnaire containing coded questions about medical, social and sexual history. Questions 
about parity, history of contraception methods used, details of their cervical examination plan 
and Pap smear results were also recorded. The questionnaire also included a section that 
examined awareness, perceived risk and practices concerning cervical cancer and cervical 
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cancer screening among the participants, these questions were the focus of this study (Appendix 
7). The interviews are ongoing from November 2009, and were administered by trained female 
interviewers. 
2.6. Study variables 
Table 1. Summary of study variables  
Variables Type  Categories 
Exposure Variables 
So
ci
o-
D
em
og
ra
ph
ic
 D
at
a 
Age Categorical 1=18- 29 2=30-39, 3=40-49, 4= >50 
Ethnicity Categorical 0=Black, 1=Other 
Marital Status Categorical 1= Single, 2=Married, 3= Cohabiting, 4=Divorced/separated, 4=Widowed 
Education Level Categorical 1=< Standard 8, 2= Standard 8 – 10 , 3=Tertiary, 4=None 
Currently Employed Categorical 0=No, 1=Yes 
Type of Employment Categorical 1==Full-time, 2=Part-time, 3=Self-employed, 4= Unknown Occupation, 
5=Student, 6= State Grant  
Currently Smoking: Categorical 0=No, 1=Yes 
Current smoking-How much? Categorical 0=<5 per day, 1=>5 per day 
Currently Drinking Alcohol  Categorical 0=No, 1=Yes 
C
lin
ic
al
 D
at
a 
Baseline WHO staging: Categorical 1= I-II, 2= III-IV  
Baseline Body mass index (BMI) (kg/m2) Categorical 1= under-weight, 2= normal, 3= over-weight 
Baseline CD4 (cells/mm3) Categorical 1= 0-50, 2= 51-100, 3= 101-250, 4= 251-350, 5= >350 
Baseline HIV viral load (VL) (copies per ml) Categorical 1= < 100000, 2= >= 100000 
Baseline Haemoglobin (Hb) (g/dL) Categorical 1= <8, 2= >=8 
Baseline Aspartate transaminase (AST) (IU/L) Categorical 1= < 40, 2= >= 40 
Baseline Alanine aminotransferase (ALT) (IU/L) Categorical 1= < 40, 2= >= 40 
Baseline Lactate levels (mmol/L) Categorical 1=0 - 2.4, 2= 2.5 – 4, 3=>=4 
HAART  regimen at HAART initiation Categorical 1=1a, 2=1a, 3=other 
Previous Pap smear results Categorical 1=Negative, 2=Moderate, 3=Severe/ICC, 4=No results 
Baseline study Pap smear results Categorical 0=Negative, 1=Moderate, 2=Severe/ICC, 3=No results 
Awareness, Perceived Risk & Practice related variables 
A
w
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s, 
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d 
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&
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Do you know about Pap smear Categorical 0=No, 1=Yes 
Have you ever had Pap smear Categorical 0=No, 1=Yes 
If you haven’t had a Pap smear, how come? Categorical 1=Don’t know, 2=Afraid it would hurt, 3=No access, 4=No time to wait in 
another queue, 5=Work, 6=Nobody to look after children, 7= No transport, 
8=Didn’t want anyone to examine me there, 9=Other, Specify_____ 
Approximately how many Pap smears have you 
had in your life time? 
Continuous N/A 
Since your first smear, can you guess how often 
you have been getting your Pap smears? 
Categorical 1=Never, 2=Yearly, 3=Once every 2-3 years, 4=Once every 4-5 years, 
5=Once every 6-10 years, 6=Less than every 10 years 
Results of previous Pap smear Categorical 1=Normal, 2=ASCUS, 3=Patient didn’t collect results, 4=AGUS, 5=ASC-
H, 6=Patient can’t remember, 7=LSIL (CIN1), 8=CIN2, 9=CIN3, 10=SCC 
Results of current Pap smear Categorical 1=Normal, 2=LSIL (CIN1), 3= HSIL, 4=ASCUS, 6=Glandular, 9=Pending, 
10=Not done, 11=SCC, ASC-H, 99= Insufficient/inadequate sample 
Do you believe Pap smears are good for health? Categorical 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
Have you ever been offered Pap smear at your 
healthcare clinic? 
Categorical 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
Has health worker ever told you that you should 
have a Pap smear in the last two years? 
Categorical 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
If you decide to get a Pap smear, where would 
you go? 
Categorical 1=Casualty, 2=HIV clinic, 3=Local primary health care clinic, 
4=Government Obstetrics and gynaecology department, 5=TB area, 
6=Other, Specify______ 
In last three years, did you try to get a Pap smear 
but were unable to get one? 
Categorical 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
Have you ever heard about HPV or Human 
Papillomavirus? 
Categorical 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
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How worried are you about getting cervical 
cancer? 
Categorical 1=Very worried, 2=Somewhat worried, 3=Not worried at all, 4=Never 
heard of cervical cancer 
2.7. Study definitions outcomes  
Awareness about Pap smear, cervical cancer and HPV:  Awareness regarding the Pap smear 
test and HPV was assessed based on whether the women report knowing what a Pap smear test 
is, and whether they have ever heard about HPV respectively. 
To ascertain Pap smear awareness study participants were asked whether they knew what a Pap 
smear is and whether they have ever heard of HPV. 
Table 2: Questions to ascertain awareness regarding Pap smear screening, cervical cancer and 
HPV  
 
Question Categories 
Do you know what a Pap smear is? 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
Have you ever heard about HPV or Human Papillomavirus? 0=No, 1=Yes, 98=Don’t know, 101=Refuse to answer 
Perceived Risk regarding cervical cancer: Perceived risk was assessed based on whether the 
women are aware of the serious implications related to developing cervical cancer based on 
how worried they were about getting cervical cancer. 
Table 3: Questions to ascertain perceived risk regarding getting cervical cancer disease 
 
Question Categories 
How worried are you about getting cervical cancer? 1=Very worried, 2=Somewhat worried, 3=Not worried at 
all, 4=Never heard of cervical cancer 
Practice regarding Pap smear screening: Practice regarding Pap smear testing was assessed 
using reported screening history of the women. In addition to this, a sub-analysis was conducted 
to see how these responses compare to 1) the recommended practice according to South African 
national cervical screening guideline based on the age of participants, and 2) the latest 
HIV/AIDS guidelines based on year of HIV diagnosis. 
The South African national cervical screening guidelines recommend three Pap smears in a 
lifetime at 10 year intervals, at 30, 40 and 50 years of age in public sector health facilities (18). 
Therefore, for women that were between the ages of 30 and 40 during the study, practice was 
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considered adequate if they have had at least one Pap smear in their life time. For women who 
were between the ages of 40 and 50 practice was considered adequate if they had more than 
one Pap smear in their life time and they last had a Pap smear no more than 10 years ago. 
The second sub-analysis assessed practice based on year of HIV diagnosis since the HIV/AIDS 
guidelines recommend cervical cancer screening on diagnosis of HIV (18). In this analysis 
practice was considered adequate if the women have had one Pap smear for every 3 year interval 
since HIV diagnosis. For example practice was considered as adequate if the women have had 
one Pap smear in their life time if they were diagnosed with HIV within a year to less than three 
years ago from the interview date. If they have been diagnosed with HIV more than three years 
ago from the interview date, practice was considered adequate if they had more than one Pap 
smear in their life time.  
Table 4: Questions to ascertain practices related to Pap smear screening 
Question Categories 
Approximately how many Pap smears have you had in your life time? Continuous 
Since your first smear, can you guess how often you have been getting 
your Pap smears? 
1=Never, 2=Yearly, 3=Once every 2-3 years, 4=Once 
every 4-5 years, 5=Once every 6-10 years, 6=Less than 
every 10 years 
The prevalence and severity of cervical cancer disease was defined using the most recent 
Pap smear results. Pap smear results were categorised into negative, moderate, or severe 
based on Pap smear results definitions. 
Table 5: Definitions of Pap smear results 
Pap Smear Results Severity Pap smear (cytology) Results Biopsy (histology) Results 
Negative:  Negative Negative 
Moderate LSIL/ASC-US/AGUS CIN I 
     Severe:  HSIL/ASC-H 
CIN II 
CIN III 
         ICC: SCC/Adenocarcinoma SCC/Adenocarcinoma 
Unknown: Results unknown Results unknown 
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Pap smear results were considered as negative if the participants’ Pap smear test or biopsy 
samples have no cell abnormalities or are reported as negative for intraepithelial lesion or 
malignancy. Results were considered as moderate if participants’ Pap test samples are ASC-
US, atypical glandular cells of undetermined significance (AGUS), LSIL or CIN I. Results 
were considered as severe if the participants’ Pap test sample results are HSIL, ASC-H, CIN II 
or CIN III; while squamous cell carcinoma (SCC) was considered as ICC. If participants did 
not recall what the results from their previous test were or they did not collect them, then the 
results were considered unknown. 
The 12 month follow-up outcome was analysed in relation to the participants’ awareness, 
perceived risk and practice related to Pap smear testing according to the following categories 
(dichotomous):  
i) Development of dysplasia at the 12 month study follow-up visit Pap smear 
screening where there was none present before 
ii) Worsening of dysplasia at the 12 month study follow-up visit Pap smear screening 
from a lower grade to a higher grade (e.g. from CIN I to CIN III)  
iii) Development of ICC at the 12 month study follow-up visit Pap smear screening 
where there was none present before  
iv) All-cause mortality for individuals enrolled in the study  
Attrition of study participants at 12 months of the study was determined using study data and 
data extracted from TherapyEdge-HIVTM the electronic medical database system used for 
patient management at the facility. These data was used to ascertain if at 12 months of study 
enrolment study participants were still alive and in HIV care or if they were deceased or lost to 
follow up (LTFU). Study participants were determined to be LTFU when more than three 
separate attempts to contact them using the contact details provided are unsuccessful and the 
missed visit is outside of the allowable window for the visit (3 months from appointment date). 
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This information was captured in the study database where a data element was included to the 
dataset to indicate what participant’s status was at 12 months of the study after the status was 
determined through study protocols and processes.  
2.8. Data processing methods and data analysis 
2.8.1. Data processing methods 
The data from the primary study was captured using Microsoft Access. Data for this study was 
transferred from the Microsoft Access database to STATA (Version 11) for analysis. Clinical 
data for all respondents was extracted from TherapyEdge-HIVTM, the electronic medical 
database system used for patient management at the facility. This data was exported to STATA 
(Version 11) for analysis. To maintain confidentiality all personal identifiers were removed 
from all data sources used in this study (original study database and TherapyEdge-HIVTM). 
A summary of socio demographic and clinical characteristics of women who participated in the 
study are described in Table 6 which also describes the proportion of missing data for each 
variable.  
2.8.2. Data analysis 
2.8.2.1. Descriptive statistics 
Descriptive statistics was used to summarise baseline characteristics. Continuous variables 
were described using mean and standard deviation if their distribution was normally distributed, 
or median and interquartile range if their distribution was not normally distributed.  Categorical 
variables were described using frequencies and percentages using tabulations in STATA. 
2.8.2.2. Inferential statistics 
Univariate analyses was used to explore the link between participant’s awareness, perceived 
risk and practices related to cervical cancer and Pap smear testing, socio-demographic and 
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clinical characteristics and most recent Pap smear results respectively. The crude odds ratio 
(OR) was reported as the outcomes were dichotomous. 
For continuous variables we first tested for normality and for non-normally distributed 
variables. The T-test was used for normally distributed variables, and non-parametric tests 
(Mann-Whitney test or Kruskal-Wallis) for non-normally distributed variables to test for 
association between the exposure and outcomes. For categorical variables the Chi-squared test 
was used provided the conditions for using this test are met (e.g. number of observations per 
cell is more than 10), if not the Fischer’s exact test or other non-parametric test were used. 
Models were developed using logistic regression incorporating factors identified as significant 
in the univariate analysis (using p <0.2) and priori variables of importance, to further determine 
socio-demographic and clinical factors associated with behaviours studied (awareness, 
perceived risk and practice related to cervical cancer and Pap smear testing). The multivariate 
model was derived by using manual forward selection. Factors were added to the model one at 
a time starting with the one with the smallest p-value checking for changes in the model 
estimates and significance levels, compared to the preceding models. The importance of each 
factor included in the model was verified by using the log likelihood test and comparing each 
model’s estimates with the point estimate from the univariate analysis model containing that 
factor. Factors that do not contribute to the model based on these criteria’s were eliminated and 
a new model fitted. A log-likelihood p-value of <0.05 was used for inclusion of a factor in the 
final model. .  
All statistical tests performed in the analysis excluded missing data. Post-estimation diagnostics 
test such the Hosmer-Lemeshow goodness of fit test; and the test to assess the model 
specification were used to examine whether the models were sound. Interaction terms were 
created fitted into the multivariate model to assess statistical significance. 
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A sub-analysis was carried out to compare the cohort of patients that were included in the study 
(the VICAR1 cohort) and the rest of the larger Themba Lethu Clinic (TLC) population that was 
not included in the study. The following socio-demographic factors were compared between 
the study cohort (VICAR1) and the TLC cohort; race, nationality, currently smoking, currently 
drinking alcohol, education level, and employment status. In addition, the following clinical 
factors were also compared between the two cohorts; HAART status, age at HAART initiation, 
HAART regimen at HAART initiation WHO staging, body mass index (BMI), haemoglobin, 
CD4, and viral load (VL). 
Analysis of attrition of study participants was conduct using time to event analysis as the 
method of analysis. The overall incidence rate attrition (death or LTFU), and incidence rates at 
specific time periods were calculated. Person time was calculated from enrolment into the study 
until earliest death, transfer out, LTFU or administrative censoring (close of dataset 31 
December 2012). 
Time to event analysis was performed using different survival techniques including Kaplan 
Meier, Log-rank test and Cox proportional hazards model. Cox proportional hazards models 
were fitted to investigate associations between baseline covariate and attrition. Global tests to 
test for validity of the proportional hazards assumptions were performed using the Schoenfeld 
residuals. Variables with p value <0.2 in univariate analysis were considered for the 
multivariate Cox models, these were added to the models to further determine factors associated 
with attrition, these added to the model one at a time starting with the one with the smallest p-
value and the adjusted (multivariate) estimates were reported. Variables which violated the 
proportional hazards assumption were excluded from the model.  
A sensitivity analysis of the of 12 month follow up study visit was conducted to determine if 
there were any significant differences between study participants that came for their 12 month 
study visit and those that did not come for their 12 month study visit. 
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2.9. Ethical consideration 
Ethical clearance for the proposed study was obtained from The University of the 
Witwatersrand Research Ethics Committee (Medicine) (HREC clearance certificate number 
M120310, 30/03/2012), and approval to use the data set from the head of Themba Lethu Clinic 
and the CEO of Helen Joseph Hospital, where Themba Lethu Clinic is situated. To maintain 
confidentiality all personal identifiers were removed from the data before secondary analysis.  
The primary study received ethical approval in October 2009 from the University of The 
Witwatersrand’s Research Ethics Committee (Medicine) (HREC clearance certificate number 
M090516, 01/09/2009). Informed consent was obtained from each participant before data 
collection. Interviewers were trained and briefed regarding handling of human subjects and 
confidentiality. In addition, the primary study procedures were conducted in accordance with 
good clinical practice and ethical consideration and handling of human subjects. This is 
documented in the protocol and standard operating procedures (SOPs) for the primary study. 
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CHAPTER 3: Results 
3.1. Descriptive analysis 
3.1.1. Study flow chart 
A total of 1202 women were screened and then enrolled in the study. Of these 4 did not have 
screening results reported as their sample was inadequate for analysis. Results were categorised 
into Negative, Moderate, Severe and ICC based on the grade of lesions found from the 
screening at enrolment, as outlined in Table 5. Figure 1 shows a summary of screening and 
enrolment outcomes of the study participants. 
 
Figure 1. Study flow chart showing enrolment and Pap screening outcomes of the study participants 
attending Themba Lethu clinic during the November 2009 to December 2012 period (n=1202). 
 
  
N=1202
Inadequate Sample
N=4
Valid Sample
N=1198
Negative
N=321
Moderate
N=474
LSIL
N=443
ASCUS
N=31
Severe
N=401
HSIL
N=371
ASC-H
N=30
ICC
N=2
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3.1.2. Participant baseline socio demographic characteristics 
Table 6 provides a summary of socio demographic and clinical characteristics of women who 
participated in the study. Tables 6 also shows the proportion of missing data for each variables. 
A total of 1202 HIV-infected women participated in the study. A majority of the women were 
black (98.09%) and of South African nationality (89.27%). The women had a mean age of 
38.14 years of age (SD ±7.67) at enrolment.  
A total of 72 (5.99%) and 88 (7.32%) women were divorced/separated, and widowed 
respectively. More than half (54.74%) of the women reported to be single, while 17.80% of the 
women reported that they were married and 14.14% reported that they were cohabiting with a 
partner.  
The majority of the women (69.38%) had between grade 10 and matric level education, with 
only 9.4% having some post-matric education. A total of 26 of the women (2.16%) reported to 
have had no education at all.  
A total of 667 (55.49%) of the women reported that they were employed. Of these 67.17% of 
these had full time employment, 27.29% had part-time employment, and 3.90% were self-
employed, while 11 (1.65%) had their occupation missing in the study database.  
A total of 125 (10.40%) of the women reported to currently drinking alcohol, the same number 
report to also taking snuff. Of these, 78.40% reported to be taking snuff less than 5 times a day 
and 16.80% reporting to be taking snuff more than 5 times a day.  
A small number reported to be smoking currently (3.49%); with 66.67% of these smoking less 
than 5 cigarettes a day, and 21.43% smoking more than 5 cigarettes a day. Appendix 1a 
provides a table of the study participants’ socio-demographic characteristics further stratified 
by the study outcomes. 
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Only the socio-demographic factors nationality, occupation, smoking frequency and snuff 
frequency had data missing; 1.75%, 1.65%, 11.90% and 4.80% data missing respectively which 
are minor rates of missing data  
3.1.3. Participant baseline clinical characteristics 
Participants’ baseline clinical data was sourced from TherapyEdge-HIVTM, the electronic 
clinical decision, support and patient management system used to manage patient data at 
Themba Lethu clinic. Participants’ baseline indicators were collected 30-90 days before, to 7 
days after HAART treatment initiation. 
The majority (51.66%) of the study participants were initiated on HAART Regimen 1a – 
stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV) the regimen recommended by the South 
African national HIV guidelines for initiating HAART treatment at the time (prior to 2012) 
(18). Only 107 (8.90%) of the women were initiated on Regimen 1b - stavudine/ lamivudine/ 
nevirapine (d4T / 3TC / NVP), none were initiated on second line therapy. Women who were 
on the NVP based regimen would mostly have reported their intentions to fall pregnant. Under 
the previous South Africa national HIV guidelines EFV was contraindicated for women at risk 
of pregnancy due to concerns related to it possibly disturbing the development of the pregnancy 
(45). 
The overall median CD4 count at HAART initiation for the group was 138 cells/mm3 (IQR 63-
205) which is significantly lower than the national HIV guideline recommended initiation CD4 
count at the time which was 200 cells/mm3 (18). The median baseline haemoglobin levels 
amongst all study participants was 11.6 g/dL (IQR 10.2-12.8), with less than 4% presenting 
with severe anaemia (<8 g/dL) at HAART initiation. A majority of the participant’s baseline 
viral load (VL) was missing (77.79%), this was because VL was not routine at HAART 
initiation as it was not the required standard of care according to the national HIV treatment 
guidelines (18). 
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Overall 285 (23.71%) of the study participants were initiated with a WHO staging of between 
III-IV. Their median body mass index (BMI) was 21.84 (IQR 19.26-25.29), and 7.15% of the 
study participant’s had a baseline BMI of less than 18.5 kg/m2 at HAART initiation. The 
median baseline Alanine aminotransferase (ALT), Aspartate transaminase (AST) and lactate 
levels were reported as 21 IU/L (IQR 15-31), 30 IU/L (IQR 24-40) and 2.26 mmol/L (IQR 1.5-
4.3) respectively. 
Participants' clinical characteristics had highest proportion of data missing, with baseline WHO 
staging, baseline BMI, baseline VL, baseline AST, and baseline lactate levels having over 25% 
rates of data missing. Clinical data for all respondents in the study was extracted from 
TherapyEdge-HIVTM, the electronic medical database system used for patient management at 
the facility.  
Table 6: Baseline socio-demographic and clinical characteristics of study participants 
attending Themba Lethu clinic during the November 2009 to December 2012 period (n=1202). 
SOCIO-DEMOGRAPHIC CHARACTERISTICS n (%)   CLINICAL CHARACTERISTICS                                         n (%) 
Age (Mean ±SD): 38.14 (±7.67)   Baseline WHO staging:    
Age groups:              I-II 558 (46.42) 
           18-29 161 (13.39)            III – IV 285 (23.71) 
           30-39 546 (45.42)            Missing 359 (29.87) 
           40-49 397 (33.03)   Baseline Body mass index (kg/m2): Median (IQR) 21.84 (19.26-25.29) 
           50+ 98 (8.15)           Underweight (<18.5) 86 (7.15) 
Race:             Normal (18.5-24.9) 478 (39.77) 
          Black 1179 (98.09)           Overweight (≥25) 328 (27.29) 
          Other 23 (1.91)           Missing 310 (25.79) 
Nationality:     Baseline CD4 (cells/mm3): Med (IQR) 138 (63-205) 
          South African 1073 (89.27)           0-50 193 (16.06) 
          Non-South African 108 (8.99)           51-100 174 (14.48) 
          Missing 21 (1.75)           101-250 472 (39.27) 
Marital status:             251-350 54 (4.49) 
           Single 658 (54.74)           >350 58 (4.83) 
           Married 214 (17.80)          Missing 251 (20.88) 
           Cohabiting 170 (14.14)   Baseline HIV viral load (copies/ml): Median (IQR) 
14000 (107-
94000) 
           Divorced/Separated 72 (5.99)          <100 000 209 (17.39) 
           Widow 88 (7.32)          ≥100 000 65 (5.41) 
Education Level:           Missing 928 (77.20) 
           < Grade 10 229 (19.05)   Baseline  Haemoglobin (g/dL): Median (IQR) 11.6 (10.2-12.8) 
           Grade10 - Matric 834 (69.38)          <8g/dL 46 (3.83) 
           Tertiary  113 (9.40)          ≥8g/dL 883 (73.46) 
            No Education 26 (2.16)          Missing 273 (22.71) 
Currently Employed:    Baseline Aspartate transaminase (IU/L): Median (IQR) 30 (24-40) 
            Yes 667 (55.49)          <40 568 (47.25) 
             Full-time     448 (67.17)          ≥40 206 (17.14) 
             Part-time     182 (27.29)         Missing 428 (35.61) 
             Self-employed     26 (3.90)   Baseline Alanine aminotransferase (IU/L): Median (IQR) 21 (15-31) 
             Missing     11 (1.65)          <40 829 (68.97) 
             No 535 (44.51)          ≥40 125 (10.40) 
Currently drinking alcohol         Missing 248 (20.63) 
             Yes 125 (10.40)   Baseline Lactate levels (mmol/L): Median (IQR) 2.26 (1.5-4.3) 
              No 1077 (89.60)         0-2.4 – Normal 271 (22.55) 
Currently Smoking:           2.5-4 – Moderately elevated 99 (8.24) 
             Yes 42 (3.49)         >4 – Severely elevated 133 (11.06) 
             <5 per day       28 (66.67)         Missing 699 (58.15) 
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             ≥5 per day       9 (21.43)   On HAART:   
             Missing       5 (11.90)          No   37 (3.12) 
             No 1160 (96.51)          Yes 1150 (96.88) 
Currently taking snuff:     HAART  regimen at HAART initiation*:    
            Yes  125 (10.40)          1a 621 (51.66) 
                              <5 per day       98 (78.40)          1b 107 (8.90) 
            ≥5 per day       21 (16.80)          Other 420 (34.94) 
            Missing       6 (4.80)          Missing                           54 (4.49) 
             No 1077 (89.60)   Previous Pap smear results:    
           Negative 523 (76.02) 
           Moderate/Severe/ICC                                                               30 (4.36) 
           Missing 135 (19.62) 
    Baseline study Pap smear results:   
           Negative                                       321 (26.71) 
          Moderate/Severe/ICC                                                               877 (72.96) 
          Missing 4 (0.33) 
     
* HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
 
3.1.4. Participant’s baseline study Pap smear results 
Figure 2a depicts the prevalence and severity of cervical cancer disease in study participant’s 
using their previous and baseline (at enrolment) study Pap smear results. The Y axis illustrates 
the number of participants while the X axis denotes the study outcome being assessed.   
A total of 688 (57.24%) of women reported having had a Pap smear screening before the study. 
Results were self-reported in most cases, and close to 20% of the participants did not have 
results reported from their previous screening. They either could not remember what the results 
were, or they never collected their results. A majority, 523 (94.58%), reported that their 
previous Pap smear test before participating in the study were negative. Only 1 (0.18%) of the 
women reported that they had severe Pap smear results in their previous Pap smear test before 
the study, and 5.24% had Pap smear results classified as moderate. 
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Figure 2a: Previous and current study baseline Pap smear screening results of study participants 
attending Themba Lethu clinic during the November 2009 to December 2012 period (Previous Pap 
smear results: n=553, Baseline study Pap smear results n=1198). 
 
A majority of the results from the baseline Pap smear screening (73.04%) were in the moderate 
or severe category, of these 33.47% of the participant’s results were classified as severe 
meaning that their Pap smear results were HSIL, ASC-H, CIN II or CIN III. This is a huge 
contrast to the results reported from previous Pap smear test before the study. In addition, two 
cases of ICC disease were reported in the baseline Pap smears. 
3.1.5. Description of participants’ awareness, perceived risk and practices 
related to cervical cancer and Pap smear testing 
Figure 2b illustrates the awareness related to Pap smear and cervical cancer screening amongst 
study participants. A total of 1202 participants were included in the analysis of awareness 
related to Pap smear and cervical cancer. The Y axis represents the number of participants while 
the X axis denotes the study outcome being assessed. 
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A total of 857 (71.30%) participants reported to be aware of Pap smear screening, with only a 
218 (18.15%) reporting to be aware of HPV. One participant (0.08%) didn’t have data to 
determine whether they were aware of HPV or not as they responded that they didn’t know 
whether they have heard of HPV or not.  Awareness regarding both Pap smear screening and 
HPV was significantly less amongst participants with only 186 (15.49%) of participants being 
aware of both the Pap smear screening test and HPV.  
 
Figure 2b: Awareness of Pap smear screening and HPV amongst study participants attending Themba 
Lethu clinic during the November 2009 to December 2012 period (Pap awareness n=1202, HPV 
awareness n=1201, Pap screening and HPV awareness n=1201).  
Figure 2c illustrates participants’ responses regarding perceived risk related to cervical cancer. 
The Y axis represents the number of participants while the X axis denotes the study outcome 
being assessed. Of the 1202 participants, 1192 participants had data available for perceived risk 
related to cervical cancer while 10 (0.83%) participants didn’t have data to determine perceived 
risk related to cervical cancer screening as they either never heard of cervical cancer (0.75%) 
or responded that they didn’t know (0.08%) how worried they were about getting cervical 
cancer disease. Of the 1192, 662 (55.54%) women were very worried, and a further 250 
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(20.97%) were somewhat worried and 280 (23.49%) were not worried about getting cervical 
cancer.  
 
Figure 2c: Perceived risk regarding cervical cancer disease amongst study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=1192). 
 
Figure 2d illustrates participants’ practice related to cervical cancer screening; practice 
according to national cervical cancer guidelines and HIV treatment guidelines respectively. The 
Y axis illustrates the number of participants while the X axis denotes the study outcome being 
assessed.  A total of 381 (36.46%) women had adequate practice according to the national 
cervical cancer guidelines. While 304 (28.57%) had adequate practice according to the national 
HIV treatment guidelines. 
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Figure 2d: Practice related to Pap smear screening amongst study participants attending Themba Lethu 
clinic during the November 2009 to December 2012 period (Pap smear screening practice according to 
cervical cancer guidelines n=1045, Pap smear screening practice according to HIV treatment guidelines 
n=1064). 
3.1.6. Comparison between study participants and TLC cohort  
A sub-analysis to compare the group of patients that were included in the study (the VICAR1 
cohort) and the rest of the larger TLC cohort population that was not included in the study was 
carried out. Table 7 provides a summary of the results. Results indicated that there were no 
major difference between the two populations, only small differences were noted in most cases. 
When comparing socio-demographic characteristics the two populations had similar 
proportions of black individuals. The TLC cohort had a slightly higher proportion (99.43%) 
compared to the VICAR1 cohort (98.09%). The VICAR1 cohort and TLC cohort were also 
similar in nationality with 90.86% and 91.09% South Africans in each cohort respectively. A 
slightly higher proportion of the TLC cohort were smokers (4.95%) compared to the VICAR1 
cohort which had 3.49% smokers. In terms of alcohol usage the VICAR1 cohort had higher 
proportion of alcohol drinkers (10.40%) than the TLC cohort (6.66%). A higher proportion 
(55.49%) of the VICAR1 cohort were employed compared to 44.31% of the TLC cohort.     
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When the two population were compared according to their clinical characteristics at HAART 
initiation, the TLC cohort median CD4 count at initiation was lower compared to the VICAR1 
cohort; 122 cells/mm3 (IQR 48-197) compared to 138 cells/mm3 (IQR 63-205). The TLC cohort 
had a lower proportions of individuals initiated on HAART at a CD4 count of ≤100 (38.59%) 
compared to the VICAR1 cohort which had over 40% individuals initiated on HAART at a 
CD4 count of ≤100. Close to 50% of the VICAR1 cohort initiated HAART at a CD4 count of 
between 100-250 compared to 43.17% in the TLC cohort, with 5.68% and 8.41% respectively 
starting at between 250-350 CD4 count. A larger portion (6.10%) of the VICAR1 cohort were 
initiated at a CD4 count of more than 350 compared to the TLC cohort (5.38%). As with the 
VICAR1 cohort a major proportion of the TLC cohort (84.7%) also had baseline VL data 
missing, for similar reasons. A higher proportion of TLC cohort (31.30%) compared to the 
VICAR1 cohort (23.72%), were initiated on HAART at a VL on >100 000.      
Compared to the VICAR1 cohort the TLC cohort had a slightly higher proportion of 
individuals, 38.83%, were initiated at WHO stage III-IV. The median BMI at HAART initiation 
amongst the TLC cohort was 21.78 (IQR 19.21-25.19) which was slightly less than the 
VICAR1 cohort 22.92 (IQR 19.88-26.67). Close to double the proportion of individuals in the 
TLC cohort (15.25%) were initiated at a baseline BMI of less than 18.5 kg/m2 compared to in 
those in VICAR1 cohort (9.62%).     
The two cohorts had the same haemoglobin levels if 11.6 d/dL (IQR 10.2-12.8) at HAART 
initiation. A higher proportion of the TLC cohort (6.61%) had haemoglobin levels less than 
8b/dL compared to the VICAR1 cohort (4.95%) at HAART initiation.        
A larger proportion of the VICAR1 cohort (96.88%) were on HAART compared to the TLC 
cohort (74.31%). Of the patients in the TLC cohort who were not in the study 49.34% were 
initiated on HAART regimen 1a compared to 54.09% of those in the VICAR1 cohort, while 
7.09% were initiated on Regimen 1b compared to 9.32% in the VICAR1 cohort. Similar to the 
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VICAR1 cohort none of the patients in the TLC cohort were initiated on second line therapy.  
When comparing the two cohorts’ age at HAART initiation both cohort had a similar mean 
ages. The TLC cohort had a mean age of 36.26 years (SD ±9.34) at HAART initiation compared 
to the VICAR1 cohort’s mean age of 36.16 (SD ±7.69).  The VICAR1 cohort had a higher 
proportion (47.22%) initiate HAART at the 30-39 age category compared to the TLC cohort 
(42.44%); 25.65% of the VICAR1 cohort compared to 21.53% of the TLC cohort were initiated 
at the 40-49 age category, while 22.61% of the VICAR1 cohort compared to 26.18% of the 
TLC cohort were initiated at the 18-29 age category. In addition, more than double of the TLC 
cohort (9.13%) were initiated at the 50+ age category compared to the VICAR1 cohort (4.5%), 
and 0.72% of the TLC cohort were initiated on HAART at the 0-17 age category while none of 
the study cohort was initiated in this age category as it was below the cut off age for inclusion 
in the study. 
Table 7: Comparison of the study participants attending Themba Lethu clinic during the November 
2009 to December 2012 period with the Themba Lethu cohort of females not included in the study  
(VICAR cohort n=1202, Themba Lethu cohort n=36134). 
Factor VICAR1 (n=1202)  n (%) 
TLC (n=21544) 
n (%) 
Race: Black 1179 (98.09) 20094 (99.43) 
           Other 23 (1.91) 116 (0.57) 
Nationality: South African 1073 (90.86) 19388 (91.09) 
                       Non-South Africa 108 (9.14) 1896 (8.91) 
Currently Smoking: Yes 42 (3.49) 818 (4.95) 
                                     No 1160 (96.51) 16509 (95.05) 
Currently drinking Alcohol: Yes 125 (10.40) 1101 (6.66) 
                                                   No 1077 (89.60) 15422 (93.34) 
Employed: Yes 667 (55.49) 9545 (44.31) 
                     No 535 (44.51) 11998 (55.69) 
Baseline WHO staging: I-II 558 (66.19) 6430 (61.17) 
                                           III - IV 285 (33.81) 4081 (38.83) 
Baseline Body mass index (kg/m2): (Med IQR) 21.84 (19.26-25.29) 22.92 (19.88-26.67) 
                                             Underweight (<18.5) 86 (9.62) 1817 (15.25) 
                                             Normal (18.5-24.9) 479 (53.58)  5934 (49.82) 
                                             Overweight (≥25) 329 (36.80) 4161 (34.93) 
Hemoglobin (Hb; g/dL):  (Med IQR) 11.6 (10.2-12.8) 11.6 (10.2-12.8) 
                                                   <8g/dL 46 (4.95) 850 (6.61) 
                                                   ≥8g/dL 883 (95.05) 12011 (93.39) 
Baseline CD4: (Med IQR) 138 (63-205) 122 (48-197)  
                              0-50 193 (20.29) 3371 (25.93) 
                              51-100 174 (18.30) 2226 (17.12) 
                             101-250 472 (49.63) 5612 (43.17) 
                             251-350 54 (5.68) 1093 (8.41) 
                             >350 58 (6.10) 699 (5.38) 
Baseline VL:  (Med IQR) 14000 (107-94000) 22022 (163-153000)  
                          <100000 209 (76.28) 2259 (68.70) 
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                          >100000 65 (23.72) 1029 (31.30) 
On HAART: No 37 (3.12) 5535 (25.69) 
                     Yes 1150 (96.88) 16009 (74.31) 
   
Age at HAART initiation (Mean SD): 36.16 (±7.69) 36.26 (±9.34) 
Age group at HAART initiation: 0-17 0 (0) 115 (0.72) 
                                                         18-29 260 (22.61) 4191 (26.18) 
                                                         30-39 543 (47.22) 6794 (42.44) 
                                                         40-49 295 (25.65) 3446 (21.53) 
                                                         50+ 52 (4.52) 1462 (9.13) 
HAART regimen at initiation*: 1a 621 (54.09) 7808 (49.34) 
                                                 1b 107 (9.32) 1122 (7.09) 
                                                 Other 420 (36.59) 6896 (43.57) 
*HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
3.2. Factors associated with the study outcomes 
3.2.1. Univariate analysis 
Univariate analysis was used to investigate the relationship between participant’s awareness, 
perceived risk and practices related to cervical cancer and Pap smear testing, and participant 
socio-demographic and clinical characteristics. The crude odds ratio (OR) was reported. 
Tables 8a, presents results of the analysis examining association between socio-demographic 
and clinical characteristic factors with the outcome awareness related to Pap smear testing and 
HPV. The significant factors associated with awareness regarding Pap smear screening were 
older age, non-black race, non-South African nationality, marital status, higher education 
levels, taking snuff, drinking alcohol, elevated baseline lactate levels at HAART initiation, and 
being initiated on HAART. In addition, the significant factors associated with HPV awareness 
were older age, higher education levels, self-employment occupation, higher smoking 
frequency, drinking alcohol, normal baseline BMI at HAART initiation, higher baseline VL at 
HAART initiation, elevated baseline ALT at HAART initiation, being initiated on HAART, 
and a non-negative baseline study Pap screening result. 
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Table 8a: Factors associated with awareness of Pap smear screening and awareness of HPV amongst of 
study participants attending Themba Lethu clinic during the November 2009 to December 2012 period. 
Factor 
Awareness about Pap Smears  Awareness about HPV 
Crude OR (95% CI) 
p-
value Adjusted OR (95% CI) 
p-
value Crude OR (95% CI)  
p-
value Adjusted OR (95% CI)  
p-
value 
Age groups: 18-29 ref  ref  ref  ref  
30-39 1.29 (0.88-1.87) 0.189 1.47 (0.74-2.92) 0.274 1.37 (0.86-2.21) 0.188 1.19 (0.48-2.95) 0.703 
40-49 1.30 (0.88-1.93) 0.184 1.59 (0.77-3.26) 0.209 1.23 (0.74-2.01) 0.422 1.13 (0.44-2.91) 0.800 
50+ 2.02 (1.12-3.35) 0.019 4.70 (1.63-13.55) 0.004 0.62 (0.28-1.35) 0.227 0.85 (0.22-3.29) 0.816 
Race:  Black  ref   ref   ref       
    Other  4.31 (1.00-18.47)  0.049  3.08 (0.38-24.86) 0.290 1.61 (0.63-4.13) 0.323     
Nationality: South African  ref    ref   ref       
                  Non-South African  0.57 (0.38-0.86) 0.007  0.41 (0.20-0.83) 0.013 1.02 (0.61-1.70) 0.933     
Marital Status: Single  ref   ref   ref       
                    Married  1.06 (0.76-1.50) 0.713  1.23 (0.70-3.11) 0.467 1.21 (0.82-1.78) 0.341     
                    Cohabiting  0.78 (0.55-1.12) 0.184  1.57 (0.79-3.11) 0.202 0.88 (0.56-1.39) 0.586     
                    Divorced/ Separated 1.54 (0.85-2.79) 0.152  1.75 (0.61-4.98) 0.295 1.33 (0.74-2.41) 0.341     
                   Widow  1.14 (0.69-1.90) 0.593  0.81 (0.39-1.69) 0.579 0.96 (0.53-1.73) 0.888     
Education Level:  < Grade 10 ref   ref   ref    ref   
                           Grade 10– Matric 1.85 (1.36-2.52) 0.000 2.12 (1.28-3.52) 0.004 3.24 (1.93-5.47) 0.000 1.06 (1.12-9.14) 0.958 
                           Tertiary  2.45 (1.45-4.12) 0.001 2.62 (1.07-6.41) 0.035 4.11 (2.14-7.89) 0.000 3.00 (0.38-23.84) 0.299 
                           None 0.90 (0.40-2.05) 0.800 0.53 (0.13-2.26) 0.392 0.50 (0.06-3.91) 0.508 3.25 (0.38-27.81) 0.281 
Currently Employed:  No ref       ref       
                                Yes  0.96 (0.75-1.23) 0.743     0.87 (0.65-1.17) 0.353     
Occupation: Full-time ref       ref    ref   
               Part-time 1.06 (0.73-1.57) 0.763   1.16 (0.73-1.82) 0.530  0.89 (0.49-1.61) 0.699 
               Self-Employed 1.83 (0.68-4.95) 0.235   2.32 (0.97-5.54) 0.058  2.12 (0.61-7.40) 0.237 
Currently Smoking:  No ref     ref       
                              Yes  1.30 (0.63-2.67) 0.477   1.43 (0.69-2.95) 0.335     
Smoking Frequency:   <5 per day ref     ref    ref   
                                      > 5 per day 1.17 (0.19-6.98) 0.866     4.8 (0.89-25.96) 0.069  5.25 (0.59-46.50)  0.195 
Currently taking snuff:  No  ref       ref       
                                          Yes  0.59 (0.40-0.86) 0.007     0.79 (0.47-1.32) 0.367     
Snuff Frequency: <5 per day ref       ref       
                              > 5 per day 0.99 (0.37-2.60) 0.997  ref   0.58 (0.12-2.76) 0.496    
Currently Drinking Alcohol: No  ref    0.67 (0.35-1.26) 0.211 ref    ref   
                                                  Yes  2.01 (1.24-3.24) 0.004     1.73 (1.13-2.65) 0.012  1.52 (0.80-2.91) 0.204 
Baseline WHO staging:   I-II  ref       ref       
                                           III -IV 0.82 (0.60-1.13) 0.226  ref   0.85 (0.58-1.25) 0.417     
Baseline BMI (kg/m2): Underweight (<18.5)    ref    1.31 (0.61-2.82) 0.490 ref    ref   
                                       Normal (18.5-24.9)  1.19 (0.73-1.95) 0.483  ref   0.69 (0.39-1.21) 0.190  0.77 (0.31-1.92) 0.577 
                                Overweight (≥25)  1.12 (0.67-1.86) 0.659  0.85 (0.59-1.23)  0.392 0.85 (0.48-1.52) 0.595  1.13 (0.44-2.90) 0.793 
Baseline CD4 (cells/mm3): 0-50   ref       ref       
                                             51-100  0.99 (0.63-1.55) 0.960     0.86 (0.50-1.49) 0.591     
                                      101-250  1.07 (0.74-1.55) 0.706         
           
           
       0.94 (0.60-1.46) 0.782     
                                      251-350  1.30 (0.63-2.69) 0.473     1.36 (0.63-2.94) 0.431     
                                      >350  1.44 (0.72-2.89) 0.299     0.65 (0.27-1.56) 0.334     
Baseline HIV viral load (copies/ml): <100 000 ref       ref    ref   
                                                             ≥100 000 1.09 (0.57-2.12) 0.788     1.68 (0.84-3.35) 0.142   2.52 (0.49-12.84) 0.266 
Hemoglobin (g/dL): <8g/dL ref       ref       
                                  ≥8g/dL 0.94 (0.49-1.82) 0.864     1.79 (0.70-4.60) 0.227     
AST (IU/L): <40 ref    ref     
                      >=40 1.19 (0.83-1.72) 0.344   0.92 (0.60-1.41) 0.692   
ALT (IU/L): <40 ref    ref   ref   
                      >=40    1.00 (0.66-1.52) 0.987   1.36 (0.86-2.16) 0.194 1.29 (0.58-2.85) 0.529 
Lactate levels (mmol/L): 0-2.4 - Normal ref  ref  ref    
                                       2.5-4 – Moderately elevated 1.07 (0.63-1.82) 0.811 1.02 (0.58-1.77) 0.956 0.69 (0.37-1.29) 0.251   
                                       >4 – Severely elevated 0.74 (0.47-1.17) 0.196 0.59 (0.36-0.96) 0.032 0.89 (0.53-1.50) 0.660   
On HAART: No ref  ref  ref  ref  
                         Yes 038 (0.16-915) <0.0010.39 (016-0.94) 0.036 1.00 (0.46-2.19) <0.0011.15 (0.37-3.58) 0.803 
HAART regimen*: 1a  ref       ref       
                  1b  0.85 (0.55-1.33) 0.482     1.09 (0.65-1.83) 0.741     
                  Other  0.94 (0.72-1.24) 0.683     0.96 (0.70-1.33) 0.817     
Baseline study Pap smear results: Negative  ref      ref   ref   
                              Moderate/Severe/ICC                                                               0.86 (0.64-1.14) 0.304  0.71 (0.52-0.98) 0.035 0.90 (0.49-1.64) 0.729 
Previous Pap smear results: Negative  ref       ref       
                                  Moderate/Severe/ICC                                                               0.89 (0.67-1.18) 0.408  1.30 (0.57-3.01) 0.533    
*HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
Tables 8b, shows results of the analysis examining association between socio-demographic and 
clinical characteristics with the outcome perceived risk related to cervical cancer and Pap smear 
testing. The significant factors for this outcome were older age, marital status, higher education 
35 
 
levels, being employed, self-employed occupation, taking snuff, higher snuff frequency, 
drinking alcohol and elevated baseline ALT at HAART initiation. 
Table 8b: Factors associated with perceived risk related to cervical cancer disease amongst of study 
participants attending Themba Lethu clinic during the November 2009 to December 2012 period. 
Factor Perceived Risk regarding cervical cancer Crude OR (95% CI) p-value Adjusted OR (95% CI) p-value 
Age groups: 18-29 ref  ref  
30-39 0.88 (0.62-1.26) 0.489 1.48 (0.84-2.61) 0.174 
40-49 0.61 (0.42-0.88) 0.008 0.91 (0.51-1.62) 0.739 
50+ 0.65 (0.40-1.07) 0.089 1.13 (0.51-2.47) 0.768 
Race:  Black  ref  ref  
    Other  1.21 (0.53-2.76) 0.647   
Nationality:  South African  Ref    
                    Non-South African  0.96 (0.65-1.41) 0.830   
Marital Status: Single  Ref  ref  
                   Married  0.83 (0.62-1.12) 0.229 0.61 (0.38-0.99) 0.062 
                  Cohabiting  1.29 (0.93-1.80) 0.132 1.40 (0.82-2.40) 0.220 
                  Divorced/ Separated 1.19 (0.73-1.93) 0.483 1.53 (0.67-3.48) 0.313 
                  Widow  0.70 (0.46-1.05) 0.086 0.65 (0.34-1.22) 0.180 
Education Level: < Grade 10 ref  ref  
                         Grade 10– Matric  1.48 (1.13-1.96) 0.005 2.60 (0.77-8.86) 0.126 
                         Tertiary  2.29 (1.44-3.63) 0.000 3.74 (1.13-12.38) 0.031 
                         None 0.76 (0.35-1.62) 0.472 6.35 (1.60-25.19) 0.125 
Currently Employed:  No Ref  ref  
                                Yes  0.80 (0.64-0.99) 0.042 0.92 (0.71-1.19) 0.523 
Occupation: Full-time ref  ref  
               Part-time 1.00 (0.72-1.38) 0.984 1.00 (0.69-1.45) 0.995 
               Self-Employed 2.10 (0.91-4.84) 0.081 2.45 (0.85-7.08) 0.098 
Currently Smoking:  No ref    
                             Yes  1.26 (069-2.30) 0.447   
Smoking Frequency:   <5 per day ref    
                                >5 per day 2.33 (0.41-13.29) 0.340   
Currently taking snuff:  No  ref  ref  
                                   Yes  0.66 (0.47-0.94) 0.022 0.55 (0.33-0.92) 0.024 
Snuff Frequency: <5 per day ref  ref  
                        >5 per day 0.53 (0.21-1.31) 0.167 0.62 (0.23-1.69) 0.348 
Currently Drinking Alcohol: No  ref  ref  
                                           Yes  1.41 (0.98-2.04) 0.063 2.53 (1.24-5.17) 0.011 
Baseline WHO staging:   I-II  ref    
                                     III -IV 1.17 (0.89-1.54) 0.266   
Baseline BMI(kg/m2): Underweight (<18.5)                          ref    
                                       Normal (18.5-24.9)  0.92 (0.59-1.44) 0.725   
                                Overweight (≥25)  0.83 (0.52-1.30) 0.411   
Baseline CD4 (cells/mm3): 0-50   ref    
                                       51-100  1.00 (0.67-1.50) 0.994   
                                       101-250  0.95 (0.69-1.32) 0.769   
                                       251-350  0.72 (0.39-1.31) 0.278   
                                       >350  0.87 (0.48-1.58) 0.658   
Baseline HIV viral load (copies/ml): <100 000 ref    
                                                              ≥100 000 0.93 (0.55-1.58) 0.795   
Hemoglobin (g/dL): <8g/dL ref    
                                   ≥8g/dL 0.72 (0.39-1.30) 0.274   
AST (IU/L): <40 ref    
                      >=40 0.94 (0.69-1.27) 0.669   
ALT (IU/L): <40 ref  ref  
                      >=40 0.76 (0.53-1.09) 0.141 0.65 (0.38-1.09) 0.104 
Lactate levels (mmol/L): 0-2.4 - Normal ref    
                                              2.5-4 – Moderately elevated 1.03 (0.66-1.61) 0.882   
                                             >4 – Severely elevated 1.20 (0.80-1.81) 0.372   
On HAART: No ref  ref  
                      Yes 072 (0.40-1.28) 0.259 0.83 (0.46-1.50) 0.534 
HAART regimen*: 1a  ref    
                  1b  1.09 (0.74-1.62) 0.666   
                  Other  1.01 (0.79-1.28) 0.961   
Baseline study Pap smear results: Negative  ref      
                              Moderate/Severe/ICC                                                               0.90 (0.70-1.16) 0.429   
Previous Pap smear results: Negative  ref       
                                  Moderate/Severe/ICC                                                               0.79 (0.40-1.56) 0.500   
 *HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
Tables 8c, shows results of the analysis examining association between socio-demographic and 
clinical characteristics with the outcome practice related to cervical cancer and Pap smear 
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testing. The significant factors associated with practice according to the national cervical cancer 
guidelines were older age, non-black race, marital status, higher education levels, a self-
employment occupation, drinking alcohol, higher baseline CD4 at HAART initiation, higher 
baseline VL at HAART initiation, elevated baseline ALT at HAART initiation, elevated 
baseline lactate levels at HAART initiation, being initiated on HAART and being initiation on 
a baseline HAART regimen of 1b. The significant factors associated with practice according to 
the HIV treatment guidelines were older age, marital status, higher education levels, part-time 
employment, taking snuff, higher snuff taking frequency, drinking alcohol, baseline WHO 
staging, higher baseline BMI at HAART initiation, higher baseline VL at HAART initiation, 
elevated baseline ALT at HAART initiation, being initiated on HAART, baseline HAART 
regimen, and having a non-negative previous Pap screening result. 
Table 8c: Factors associated with practice related to Pap smear screening amongst of study participants 
attending Themba Lethu clinic during the November 2009 to December 2012 period. 
Factor 
Practice according to national cervical cancer guidelines Practice according to HIV treatment guidelines 
Crude OR (95% CI) p-value Adjusted OR (95% CI) 
p-
value Crude OR (95% CI)  p-value Adjusted OR (95% CI)  p-value 
Age groups: 18-29 ref  ref  ref  ref  
  30-39 10.81 (5.50-21.24) <0.001 12.23 (4.00-37.35) <0.0011.35 (0.85-2.15) 0.201 1.40 (0.37-5.32) 0.619 
  40+ 1.88 (0.93-3.81) 0.078 1.32 (0.42-4.11) 0.637 1.74 (1.09-2.79) 0.021 1.37 (0.35-5.40) 0.655 
  50+ 6.38 (4.76-8.54) 0.098 5.74 (2.35-7.15) 0.425 2.83 (1.56-5.13) 0.001 2.32 (0.44-12.34) 0.320 
Race:  Black  ref  ref  ref     
    Other  2.11 (0.90-4.94) 0.084 1.05 (0.26-4.24) 0.942 1.75 (0.74-4.14) 0.201    
Nationality: South African  ref    ref     
     Non-South African  1.05 (0.66-1.67) 0.837   0.93 (0.57-1.50) 0.752   
Marital Status: Single  ref  ref  ref  ref  
                   Married  1.21 (0.87-1.68) 0.252 1.27 (0.68-2.37) 0.449 1.10 (0.77-1.58) 0.600 1.18 (0.46-3.02) 0.728 
                  Cohabiting  0.72 (0.48-1.07) 0.104 0.36 (0.17-0.75) 0.006 0.75 (0.49-1.14) 0.178 0.83 (0.22-3.15) 0.788 
                  Divorced/ Separated 0.83 (0.49-1.39) 0.476 1.50 (0.53-4.25) 0.451 1.49 (0.86-2.57) 0.151 3.42 (0.90-12.93) 0.070 
                  Widow  0.52 (0.31-0.87) 0.013 0.53 (0.21-1.35) 0.186 1.10 (0.65-1.85) 0.726 0.68 (0.16-2.94) 0.606 
Education Level: < Grade 10 ref  ref   ref  ref  
                         Grade 10 – Matric  1.77 (1.26-2.51) 0.001 1.18 (0.11-12.26) 0.892 0.68 (0.49-0.96) 0.027 0.48 (0.20-1.12) 0.089 
                         Tertiary  5.15 (3.03-8.73) <0.001 1.26 (0.12-12.75) 0.844 1.38 (0.84-2.28) 0.206 2.52 (0.70-9.06) 0.158 
                         None 0.50 (0.14-1.75) 0.277 3.08 (0.27-35.34) 0.366 0.77 (0.31-1.94) 0.582 6.30 (0.47-83.84) 0.163 
Currently Employed:  No ref    ref     
                                Yes  0.88 (0.68-1.13) 0.316   1.09 (0.84-1.43) 0.520    
Occupation: Full-time ref  ref  ref   ref   
               Part-time 1.06 (0.72-1.56) 0.758 0.85 (0.52-1.41) 0.538 0.69 (0.45-1.04) 0.079 0.64 (0.39-1.08) 0.094 
               Self-Employed 2.27 (0.96-5.40) 0.062 2.95 (0.82-10.66) 0.040 1.49 (0.60-3.75) 0.393 1.71 (0.52-5.65) 0.376 
         
Currently Smoking:  No ref    ref     
                             Yes  1.04 (0.50-2.15) 0.914   1.42 (0.73-2.77) 0.304    
Smoking Frequency:   <5 per day ref    ref     
                                > 5 per day 2.67 (0.46-15.35) 0.272   0.36 (0.06-2.05) 0.248    
Currently taking snuff:  No  ref    ref  ref   
                                   Yes  0.90 (0.60-1.35) 0.616   0.64 (0.40-1.02) 0.061 0.63 (0.20-2.00) 0.432 
Snuff Frequency: <5 per day ref    ref  ref   
                        > 5 per day 1.86 (0.68-5.06) 0.224   0.36 (0.08-1.67) 0.191 0.41 (0.15-2.45)  0.652 
Currently Drinking Alcohol: No  ref  ref  ref  ref   
                                           Yes  2.01 (1.34-3.04) 0.001 1.27 (0.52-3.07) 0.599 1.52 (1.00-2.32) 0.050 1.31 (0.39-4.37) 0.657 
Baseline WHO staging:   I-II  ref    ref  ref   
                                     III -IV 0.91 (0.66-1.25) 0.552   0.78 (0.56-1.08) 0.139 1.00 (0.46-2.16) 0.991 
Baseline BMI(kg/m2): Underweight (<18.5)                          ref    ref  ref   
                                       Normal (18.5-24.9)  1.40 (0.80-2.46) 0.235   1.35 (0.77-2.38) 0.291 0.43 (0.11-1.62) 0.214 
                                Overweight (≥25)  1.23 (0.69-2.18) 0.483   1.72 (0.97-3.05) 0.066 0.53 (0.13-2.13) 0.369 
Baseline CD4 (cells/mm3): 0-50   ref  ref  ref     
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                                       51-100  1.23 (0.78-1.93) 0.381 0.55 (0.55-55.50) 0.358 1.04 (0.64-1.68) 0.871    
                                       101-250  0.93 (0.63-1.36) 0.705 0.49 (0.16-1.48) 0.204 1.24 (0.84-1.83) 0.274    
                                       251-350  0.94 (0.46-1.92) 0.865 8.60 (0.96-77.31) 0.555 1.19 (0.57-2.46) 0.648    
                                       >350  1.53 (0.80-2.92) 0.197 0.33 (0.38-2.86) 0.315 0.99 (0.48-2.02) 0.973    
Baseline HIV viral load (copies/ml):  
                                                        <100 000 ref  ref  ref  ref   
                                                        ≥100 000 0.61 (0.32-1.17) 0.138 4.67 (0.39-55.50) 0.223 0.53 (0.26-1.10) 0.087 0.75 (0.31-1.81) 0.527 
Hemoglobin (g/dL): <8g/dL ref    ref     
                                   ≥8g/dL 0.70 (0.35-1.39) 0.304   0.88 (0.46-1.69) 0.706    
AST (IU/L): <40 ref    ref     
                      >=40 1.25 (0.88-1.77) 0.222   1.03 (0.71-1.48) 0.895   
ALT (IU/L): <40 ref  ref  ref  ref  
                      >=40 1.66 (1.10 -2.51) 0.015 1.74 (0.61-5.00) 0.304 1.33 (0.88-2.02) 0.179 1.73 (0.63-4.7) 0.287 
Lactate levels (mmol/L): 0-2.4 - Normal ref  ref  ref    
                                  2.5-4 – Moderately elevated 1.05 (0.64-1.74) 0.838 1.08 (0.61-1.91) 0.789 0.92 (0.54-1.57) 0.755   
                                  >4 – Severely elevated 0.69 (0.43-1.01) 0.120 0.75 (0.43-1.28) 0.290 0.73 (0.43-1.21) 0.221   
ON HAART: No ref  ref  ref  ref  
                       Yes 0.39 (0.20-0.79) 0.009 0.17 (0.06-0.55) 0.003 0.53 (0.22-1.26) 0.150 0.79 (0.29-2.12) 0.638 
HAART regimen*: 1a  ref  ref  ref  ref   
                  1b  1.53 (0.97-2.41) 0.065 1.05 (0.63-1.73) 0.863 0.77 (0.46-1.28) 0.310 1.01 (0.19-5.27) 0.993 
                  Other  1.19 (0.90-1.57) 0.227 0.98 (0.71-1.34) 0.900 1.26 (0.94-1.68) 0.118 1.02 (0.39-2.66) 0.972 
Baseline study Pap smear results: Negative  ref      ref      
                        Moderate/Severe/ICC                                                               1.05 (0.79-1.39) 0.727  1.13 (0.84-1.53) 0.424   
Previous Pap smear results: Negative  ref       ref    ref   
                        Moderate/Severe/ICC                                                               0.81 (0.37-1.81) 0.611  1.66 (0.77-3.60) 0.196 5.42 (0.65-45.41) 0.119 
*HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
 
3.2.2. Multivariate analysis 
Factors associated with awareness, perceived risk and practice related to cervical cancer and 
Pap screening amongst our study participants are listed in Tables 8a – 8c.  
In the analysis of awareness related to Pap smear screening the significant factors were older 
age, non-South African nationality, an education level higher than grade 10, and severely 
elevated lactate levels at HAART initiation and being initiated on HAART. Compared to the 
18-29 age group women in the 50+ age group had over four and a half times more likely to be 
aware of Pap smear screening (aOR=4.70, 95% CI 1.63-13.55). Compared to South Africans 
in the study, non-South Africans were 59% less likely to be aware of Pap smear screening 
(aOR=0.41, 95% CI 0.20-0.83). Having a grade 10 to matric level education increased the 
likeliness of awareness regarding Pap smear screening to just over two times compared to those 
with less than a grade 10 education (aOR=2.12, 95%CI 1.28-3.52); the likeliness of Pap smear 
awareness was also over two times more amongst the participants that had a tertiary level 
education as compared to those with less than a grade 10 education (aOR=2.62, 95%CI 1.07-
6.41). Compared to those that had normal baseline lactate levels, those with severely elevated 
baseline lactate levels were 41% less likely to be aware of Pap smear screening (aOR=0.59, 
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95% CI 0.36-0.96). Those that are initiated on HAART were 61% less likely to be aware of 
Pap smear screening than those that were not initiated on HAART (aOR=0.39, 95% CI 0.16-
0.94). 
In the analysis of perceived risk related to cervical cancer disease the significant factors 
identified were higher education levels, taking snuff and drinking alcohol. Compared to having 
less than a grade 10 education, having a tertiary education increased perception of risk related 
to cervical cancer disease by close to four times (aOR=3.74, 95%CI 1.13-12.38). Compared to 
those that did not take snuff those that took snuff were 45% less perceived risk related to getting 
cervical cancer disease (aOR=0.55, 95%CI 0.33-0.92). While those who reported that they 
currently drink alcohol had over two and a half times increased perceived risk related to getting 
cervical cancer disease compared to those that did not drink alcohol (aOR=2.53, 95% CI 1.24-
5.17). 
In the analysis of practice related to cervical cancer and Pap smear testing according to the 
national cervical cancer guidelines significant factors identified were older age, marital status, 
self-employment occupation and being initiated on HAART. Those in the 30-39 age group 
were over fourteen times more likely to have adequate practice according to the national 
cervical cancer guidelines compared to those in the 18-29 age group (aOR=12.23, 95%CI 4.00-
37.35), however this association was imprecise.  Compared to those that were single at 
enrolment in the study, those that reported to be cohabiting with a partner were over 60% times 
less likely to have adequate practice according to the national cervical cancer guidelines 
(aOR=0.36, 95%CI 0.17-0.75). Participants that were self-employed were almost three times 
more likely to have adequate practice according to the national cervical cancer guidelines than 
those who had full time employment (aOR=2.95, 95%CI 0.82-10.66). Those that are initiated 
on HAART were 83% less likely to have adequate Pap smear screening practice according to 
the national cervical cancer guidelines than those that were not initiated on HAART 
(aOR=0.17, 95% CI 0.06-0.55). 
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In the analysis of awareness related to HPV, and the analysis of practice according to the 
national HIV treatment guidelines none of the factors proved to be significantly associated with 
both outcomes. Results from these analyses are summarised in Table 8a and 8c respectively. 
3.3. Disease progression at 12 Month  
The 12 month follow-up outcome, disease progression, was analysed in relation to the 
participants’ awareness, perceived risk and practice related to Pap smear testing, specifically:  
i) Development of dysplasia where there was none present before 
ii) Worsening of dysplasia from a lower grade to a higher grade  
iii) Development of ICC where there was none present before 
A total of 688 participants had a 12 month follow study up visit. This represents 57.24% of the 
total participants enrolled in the study at baseline. Earliest enrolment of participants into the 
study was November 2009, and the latest enrolment was in December 2012 therefore as of  the 
31st  October 2013 (the date of which the 12 month follow up data was collected up until) all 
participants were eligible for a 12 month follow up study visit. Figure 3 represents a summary 
of participant’s 12 months of follow up visit and screening outcomes. 
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Figure 3: Study flow chart showing 12 month follow-up enrolment and Pap smear screening outcomes 
of study participants attending Themba Lethu clinic during the November 2009 to December 2012 
period. 
Out of the 1202 study participants 688 (57.24%) participants had a 12 month follow up visit 
for the study. Of these 685 (99.56%) had a valid sample collected during Pap smear screening 
and had Pap screening results recorded in the study database. A total of three participants did 
not have a valid sample, of these two did not undergo Pap screening during their 12 month 
follow up visit and one had an inadequate sample collected during the screening procedure. Out 
of the 685 study participants who had a result reported from their 12 month follow up study 
Pap smear 107 (15.62%) participants had negative Pap smear results. The majority of the 
participants, 483 (70.51%), had moderate results and 95 (13.89%) had severe results.  
Out of the 685 participants with a valid sample collected during  the 12 month follow up Pap 
smear screening a total of 681 (99.42%) of the study participants that had a valid sample were 
included in the analysis. The four participants who were not included in the analysis for disease 
progression did not have baseline Pap results as they had inadequate samples collected, 
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therefore it could not be determine whether they had worsening of their Pap smear screening 
results from their baseline Pap smear screening results. A total of 232 (34.07%) participants 
had worsening of their Pap smear results compared to their baseline study Pap smear results 
(disease progression). Of the rest of the study participants included in the analysis, 449 
(65.93%) did not have any disease progression noted (Figure 3). Of these 449 participants who 
did not have any disease progression noted a majority, 366 (53.74%), had their results stay the 
same as their baseline results from their Pap smear screening from the preceding 12 months 
while 83 (12.19%) had their results improve from their Pap smear screening from the preceding 
12 months.  
A total of 514 (42.76%) study participants did not have a 12 month follow up visit conducted. 
Out of these 102 (19.84%) LTFU, 46 (8.95%) became pregnant thereby making them no longer 
eligible to be in the study. Study participants were determined to be LTFU when more than 
three separate attempts to contact them using the contact details provided are unsuccessful and 
the missed visit is outside of the allowable window for the visit (3 months from appointment 
date). The rest of the study participants who did not have a 12 month follow up study visit 
conducted were removed from the study because they had relocated (2.53%), transferred out of 
the study site (0.97%) or were treated off study (62.06%) because they had severe screening 
results from their baseline Pap smear screening results and needed to be treated. They were 
where either referred to VICAR 2 or treated elsewhere; treated at other health facilities outside 
both VICAR 1 and VICAR 2 studies. A total of seven (1.36%) participants withdrew their 
consent to be part of the study as they were no longer interested in participating in the study.  
A further 15 (2.92%) participants were unable to be treated because of the severity of the 
cervical cancer disease detected during their baseline Pap screening, and therefore did make up 
part of the 12 month follow study visit data set. These are the patients who had severe screening 
results from their baseline Pap smear screening results and needed to be treated, however the 
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doctor had difficulty performing treatment procedures and were referred elsewhere for further 
management. 
3.3.1. Descriptive analysis: disease progression at 12 month  
Of the 232 participants who experienced disease progression at 12 months, the majority 173 
(74.57%) knew what a Pap smear was at study enrolment while 25.43% were not aware. Less 
participants, 50 (21.55%), that had disease progression noted were aware of HPV at study 
enrolment. Out of those that did not have disease progression noted at 12 months a majority, 
76.17%, were aware what a Pap smear was at study enrolment while only 17.37% were aware 
of HPV at study enrolment.  
A majority 128 (55.90%)  of the study participants that had disease progression noted on their 
12 month Pap screening were very worried about getting cervical cancer disease at study 
enrolment while 19.65% were somewhat worried about getting cervical cancer disease at study 
enrolment, and 24.45% were not worried at all about getting cervical cancer disease at study 
enrolment. As with those that had disease progression, the majority (53.93%) of those that did 
not have disease progression in their 12 month Pap screening were very worried about getting 
cervical cancer disease at study enrolment, while 23.82% of these were not worried at all about 
getting cervical cancer disease at study enrolment. 
The majority of both study participants who had disease progression noted (63.68%) and those 
that did not have disease progression (61.90%) had inadequate practice according to the 
national cervical cancer guidelines at study enrolment. While higher proportions of just over 
70% of those that had disease progression and those that didn’t, had inadequate practice 
according to the national HIV treatment guidelines at study enrolment. Results from these 
analyses are summarised below in Tables 9a-9e. Included in Tables 9a-9e are also estimates for 
the univariate and multivariate analysis to assess if there is significant association with the main 
study outcomes as assessed at the beginning of the study (awareness, perceived risk and 
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practices related to cervical cancer and Pap screening) and disease progression at 12 months of 
the study the crude and adjusted odds ratio (OR) were reported. No association was noted 
between the main study outcomes and disease progression at 12 months of the study. 
Table 9a: Association between study participants’ disease development and Pap smear awareness at 12 
month for study participants attending Themba Lethu clinic during the November 2009 to December 
2012 period (n=681). 
Factor 
Disease Development at 
12month Follow up  
Univariate and Multivariate Analysis – Disease 
Development at 12 month follow up 
Progressed 
232 (34.07) 
Not 
Progressed 
449 (65.93) 
Crude OR (95% CI) p-value Adjusted OR  (95% CI) 
p-
value 
Pap Awareness:            
Aware 173 (74.57) 342 (76.17) ref 
0.645 
ref 
0.824 
Not Aware 59 (25.43) 107 (23.83) 0.92 (0.64-1.32) 0.91 (0.47-2.01) 
 
Table 9b: Association between study participants’ disease development and HPV awareness at 12 month 
for study participants attending Themba Lethu clinic during the November 2009 to December 2012 
period (n=681). 
Factor 
Disease Development at 
12month Follow up  
Univariate and Multivariate Analysis – Disease 
Development at 12 month follow up 
Progressed 
232 (34.07) 
Not 
Progressed 
449 (65.93) 
Crude OR (95% CI) p-value Adjusted OR  (95% CI) 
p-
value 
HPV Awareness           
Aware 50 (21.55) 78 (17.37) ref 
0.187 
ref 
0.487 
Not Aware 182 (78.45) 371 (82.63) 1.31 (0.88-1.94) 1.39 (0.55-3.51) 
 
Table 9c: Association between study participants’ disease development and perceived risk related to 
cervical cancer diseaseat 12 month for study participants attending Themba Lethu clinic during the 
November 2009 to December 2012 period (n=674). 
Factor 
Disease Development at 
12month Follow up  
Univariate and Multivariate Analysis – Disease 
Development at 12 month follow up 
Progressed 
229 (33.98) 
Not 
Progressed 
445 (66.02) 
Crude OR (95% CI) p-value Adjusted OR  (95% CI) 
p-
value 
Perceived Risk           
Not Worried at All 56 (24.45) 106 (23.82) ref   ref   
Somewhat Worried 45 (19.65) 99 (22.25) 0.86 (0.53-1.39) 0.538 1.96 (0.75-5.15) 0.171 
     Very Worried 128 (55.90) 240 (53.93) 1.01 (0.68-1.49) 0.962 0.70 (0.31-1.57) 0.383 
 
Table 9d: Association between study participants’ disease development and Pap smear screening 
practice according to national cervical cancer guidelines at 12 month for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=600). 
Factor Disease Development at 12month Follow up  
Univariate and Multivariate Analysis – Disease 
Development at 12 month follow up 
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Progressed 
201 (33.50) 
Not 
Progressed 
399 (66.50) 
Crude OR (95% CI) p-value Adjusted OR  (95% CI) 
p-
value 
Practice according to the 
national cervical cancer 
guidelines 
           
Adequate 73 (36.32) 152 (38.10) ref 
0.671 
ref 
0.558 
Not Adequate 128 (63.68) 247 (61.90) 0.93 (0.65-1.32) 1.32 (0.53-3.29) 
 
Table 9e: Association between study participants’ disease development and Pap smear screening 
practice according to national HIV treatment guidelines at 12 month for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=611). 
Factor 
Disease Development at 
12month Follow up  
Univariate and Multivariate Analysis – Disease Development 
at 12 month follow up 
Progressed 
208 (34.04) 
Not 
Progressed 
403 (65.96) 
Crude OR (95% CI) p-value Adjusted OR  (95% CI) 
p-
value 
Practice according to 
national HIV treatment 
guidelines 
           
Adequate 61 (29.33) 119 (29.53) ref 
0.959 
ref 
0.688 
Not Adequate 147 (70.67) 284 (70.47) 0.99 (0.69-1.43) 1.17 (0.55-2.50) 
3.3.2. Univariate: disease progression at 12 month  
Univariate analysis was conducted to assess association between disease progression at 12 
months of study and the baseline covariates assessed in the main analysis (participants’ baseline 
socio demographic and baseline clinical characteristics). The crude odds ratio (OR) was 
reported. 
Non-South African nationality, being employed, part-time occupation, higher snuff taking 
frequency, elevated haemoglobin at HAART initiation, a non-negative Pap screening result at 
study baseline Pap screening, and not being aware of HPV at study enrolment were found to 
have significant association with disease progression at 12 months of the study. Results from 
these analyses are summarised above in Table 9f.  
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3.3.3. Multivariate analysis: disease progression at 12 month  
There was only one significant factor that was found to be significantly associated with disease 
progression in the multivariate analysis, this was having a non-negative baseline study Pap 
smear screening at study enrolment. 
Compared to those that had a negative baseline study Pap smear at study enrolment those that 
had  a moderate to severe baseline study Pap smear at enrolment into the study were  92% less 
likely  to have disease progression at their 12 month Pap smear screening (aOR=0.08, 95%CI 
0.05-0.13). Results from this analysis are provided in Table 9f. 
Table 9f: Factors association with study participants’ disease development at 12 month for study 
participants attending Themba Lethu clinic during the November 2009 to December 2012 period 
(n=681). 
Factor Disease progression at 12 months of the study Crude OR (95% CI)  p-value Adjusted OR (95% CI)  p-value 
Age groups: 18-29 ref    
30-39 0.82 (0.49-1.37) 0.457   
40-49 0.83 (0.49-1.39) 0.468   
50+ 0.71 (0.35-1.44) 0.344   
Race:  Black  ref       
    Other  0.52 (0.14-1.89) 0.321     
Nationality: South African  ref    ref   
                  Non-South African  1.58 (0.88-2.83) 0.124  1.79 (0.73-4.38) 0.206 
Marital Status: Single  ref       
                    Married  1.19 (0.79-1.80) 0.397     
                    Cohabiting  0.85 (0.52-1.39) 0.526     
                    Divorced/ Separated 1.17 (0.59-2.29) 0.656     
                   Widow  0.74 (0.38-1.46) 0.389     
Education Level:  < Grade 10 ref     
                           Grade 10– Matric 1.07 (0.72-1.60) 0.725   
                           Tertiary  0.83 (0.43-1.58) 0.567   
                           None 1.73 (0.55-5.44) 0.347   
Currently Employed:  No ref    ref   
                                Yes  0.67 (0.49-0.92) 0.014  1.24 (0.77-2.02) 0.378 
Occupation: Full-time ref   ref  
               Part-time 0.67 (0.40-1.12) 0.125 0.90 (0.42-1.93) 0.778 
               Self-Employed 0.74 (0.23-2.39) 0.615 1.51 (0.34-6.81) 0.590 
Currently Smoking:  No ref     
                              Yes  0.91 (0.39-2.14) 0.824   
Smoking Frequency:   <5 per day ref     
                                      > 5 per day 1.22 (0.16-9.47) 0.848   
Currently taking snuff:  No  ref     
                                          Yes  0.92 (0.54-1.55) 0.753   
Snuff Frequency: <5 per day ref   ref  
                              > 5 per day 2.5 (0.70-8.92) 0.158 2.59 (0.30-22.29) 0.387 
Currently Drinking Alcohol: No  ref     
                                                  Yes  1.14 (0.68-1.92) 0.621   
Baseline WHO staging:   I-II  ref     
                                           III -IV 0.82 (0.61-1.39) 0.697   
Baseline BMI (kg/m2): Underweight (<18.5)    ref     
                                       Normal (18.5-24.9)  0.85 (0.44-1.64) 0.631   
                                Overweight (≥25)  0.67 (0.34-1.32) 0.244   
Baseline CD4 (cells/mm3): 0-50   ref     
                                             51-100  0.80 (0.43-1.46) 0.462   
                                      101-250  0.83 (0.51-1.33) 0.432   
                                      251-350  0.65 (0.26-1.61) 0.355   
                                      >350  0.82 (0.36-1.86) 0.632   
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Baseline HIV viral load (copies/ml): <100 000 ref     
                                                             ≥100 000 0.85 (0.39-1.83) 0.674   
Hemoglobin (g/dL): <8g/dL ref   ref  
                                  ≥8g/dL 0.55 (0.25-1.22) 0.141 0.49 (0.77-2.02) 0.151 
AST (IU/L): <40 ref    
                      >=40 1.36 (0.88-2.09) 0.164   
ALT (IU/L): <40 ref    
                      >=40    1.30 (0.74-2.27) 0.359   
Lactate levels (mmol/L): 0-2.4 - Normal ref    
                                       2.5-4 – Moderately elevated 1.05 (0.58-1.88) 0.872   
                                       >4 – Severely elevated 0.73 (0.42-1.28) 0.273   
On HAART: No ref    
                      Yes 0.97 (0.40-2.31) 0.938   
HAART regimen*: 1a  ref     
                  1b  0.80 (0.45-1.44) 0.461   
                  Other  0.87 (0.61-1.25) 0.451   
Baseline study Pap smear results: Negative  ref   ref  
                              Moderate/Severe/ICC                                                               0.07 (0.05-0.10) <0.001 0.08 (0.05-0.13) <0.001 
Previous Pap smear results: Negative  ref     
                                  Moderate/Severe/ICC                                                               0.711 (0.27-1.87) 0.489   
 r    
Pap Awareness: Aware ref    
          Not Aware 0.92 (0.64-132) 0.645   
HPV awareness:  Aware ref  ref  
                              Not aware 1.31 (0.88-1.94) 0.187 1.51 (0.84-2.73) 0.171 
     
Perceived Risk : Not Worried at All ref ref   
           Somewhat Worries 0.86 (0.53-1.39) 0.538   
                             Very Worried 1.01 (0.68-1.49) 0.962   
Practice according to the national cervical cancer 
guidelines:     
             Adequate ref ref   
             Not Adequate 0.93 (0.65-1.32) 0.671   
Practice according to national HIV treatment 
guidelines:     
             Adequate ref ref   
                               Not Adequate 0.99 (0.69-1.43) 0.959   
*HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
A sensitivity analysis was conducted among patients that did not have a 12 month visit (n=514) 
and thus did not have their disease progression assessed, to evaluate whether excluding them 
had any impact on the estimates in the main analysis of disease progression. Although there are 
some minor deviations in estimates from main analysis, the confidence intervals for the 
sensitivity analysis look similar to the main analysis therefore it is unlikely that excluding those 
that did not have a 12 month follow up visit biased the main analysis, the results from this 
analysis are listed in Appendix 2b.  
3.4. Analysis of attrition 
During the study period a total of 7 women enrolled in the study died out of the 1202 enrolled 
in the study, this equates to 0.58% of study participants who became deceased by the end of 
the study. This was all-cause mortality and the deceased participants didn’t necessarily die of 
cervical cancer disease related causes, in most cases data on the cause of death could not be 
acquired. 
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All study participants’ deaths occurred in the 30-39 years age group. The mean time to death 
from enrolment in the study was 156 days (SD ±126.28 days). The earliest a participant died 
was 1 month after enrolment into the study, and the latest that a participant died was 13.5 
months after enrolment into the study. Although this was outside the 12 month study follow 
up, in general study participants were given some leeway (a maximum of 3 months) to be able 
to return for their 12 month study follow up visit and still be included in the 12 month follow 
up analysis. The mortality observed corresponds to an overall incidence rate of 0.048 (95% CI: 
0.023-0.101) cases per 100 person months of follow-up. 
 Figure 4 provides survival estimates for the study population. 
 
Figure 4. Kaplan Meier estimates of mortality by 12 month study follow up for study participants 
attending Themba Lethu clinic during the November 2009 to December 2012 period (n=7). 
Survival analysis to assess estimates for the outcome death did not yield meaningful results as 
the sample size was so small and therefore did not have sufficient power for meaningful 
analysis. The study was an analysis of secondary data we therefore did not have control over 
the sample size determination.  
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Further analysis was conducted to examine all-cause attrition. The number of study participants 
that were alive and in HIV care were compared to those that were no longer alive and in HIV 
care (those that died, or were lost to follow up).  Table 10 below summarises period incidence 
for attrition for the study population.  
Out of 1202 study participants followed up for a total of 1835 person-months, a total of 109 
cases of attrition were observed, corresponding to an overall incidence rate of 5.95 (95% CI: 
4.93-7.18) cases per 100 person months of follow-up. Study participants were determined to be 
LTFU when more than three separate attempts to contact them using the contact details 
provided are unsuccessful and the missed visit is outside of the allowable window for the visit 
(3 months from appointment date). 
 
Table 10. Period incidence rates of attrition at specified time points per 100 person months for 
study participants attending Themba Lethu clinic during the November 2009 to December 2012 
period (n=109) 
Period  
(months) 
Person time 
 (months) 
Failures Surviving Period incidence 
rate (per 100 
person months) 
95% CI 
0-3 months 324.54 4 106 1.23 0.46-3.28 
3-6 months 309.95 3 103 0.97 0.31-3.00 
6-9 months 
9-12 months 
300.15 
289.23 
3 
6 
100 
94 
1.00 
2.07 
0.32-3.10 
0.93-4.62 
12-15 months 258.20 11 83 4.26 2.36-7.69 
>15 months 349.54 82 0 23.46 18.89-29.13 
Total 1831.61 109 0 5.95 4.93-7.18 
 
The incidence rate was the highest during the period >15 months at 23.46 per 100 person 
months (95% CI 18.89-29.13). The incidence rate was at its lowest during the 3-6 months 
period at 0.97 per 100 person months (95% CI 0.31-3.00). The majority of study participants 
(46.79%) became decease or LTFU after 12 months in the study..  
The Kaplan Meier curve was used to determine the overall survival for the study population. 
Figure 5 shows the overall survival of patients during the study period. 
49 
 
 
Figure 5. Kaplan Meier estimates for all-cause attrition (death and LTFU) by 12 month study follow up 
for study participants attending Themba Lethu clinic during the November 2009 to December 2012 
period (n=109). 
 
3.4.1. Predictors of all-cause attrition 
Attrition was also further assessed according to the main study outcomes; awareness, perceived 
risk and practice related to Pap smear testing as assessed as at the beginning of the study, and 
baseline covariates, namely study participants’ baseline socio-demographic and clinical 
characteristic at HAART initiation.   
When attrition was assessed according to the main study outcomes a slightly higher proportion 
(55.96%) of the study participant became deceased or LTFU by the end of the study were aware 
what a Pap smear was at study enrolment, while a majority (83.49%) were not aware of HPV 
at study enrolment.  A total of 59 (54.63%) of study participants that became deceased or LTFU 
by the end of the study were very worried about getting cervical cancer disease at study 
enrolment, while 12.96% were somewhat worried about getting the disease at study enrolment. 
A total of 35 (32.41%) were not worried at all about getting the disease at study enrolment. In 
addition, a majority (73.20%) of them had inadequate Pap screening practice according to both 
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the national cervical cancer guidelines and the national HIV treatment guidelines at study 
enrolment (80%). The above results and results from the descriptive analysis of attrition 
according to baseline covariates are summarised below in Tables 11. 
The equality of survival curves were tested using log rank tests. Results are summarised in 
appendix 2c. From the results, a p-value <0.05 was considered significant. Significant 
difference in Kaplan Meier survival curves between different groups were only noted for the 
covariate baseline study Pap screening results, this Kaplan Meier curve is listed below. 
 
Figure 6a. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants baseline study Pap screening results at study enrolment for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=109). 
 
Study participants with a negative baseline study Pap smear at study enrolment were less likely 
to become deceased or LTFU than those with a moderate and severe results. The log rank test 
of equality of survival functions was significant (p=0.043). 
Kaplan Meier curves were used to determine survival for the study population according to 
main study outcomes; Pap smear and HPV awareness, perceived risk of getting cervical cancer 
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disease, and practice according to nation HIV treatment and cervical cancer guidelines. Figure 
6b-6d shows the survival of study participants during the study period according to the main 
study outcomes. 
 
Figure 6b. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants awareness of Pap smear screening at study enrolment for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=109). 
 
Study participants that were aware of the Pap smear screening test at study enrolment had 
similar risk to become deceased or LTFU to study participants that were not aware of Pap 
smear screening (p=0.633). 
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Figure 6c. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants awareness of HPV at study enrolment for study participants attending Themba Lethu clinic 
during the November 2009 to December 2012 period (n=109). 
Study participants that were aware of HPV at study enrolment had similar risk to become 
deceased or LTFU to study participants that were not aware of Pap smear screening 
(p=0.988).
 
Figure 6d. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants perceived risk of getting cervical cancer at study enrolment for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=109). 
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Study participants that were very worried about getting cervical cancer disease at study 
enrolment were more likely to become deceased or LTFU than those that were somewhat 
worried and those that were not worried at all, however this difference between risk was not 
significantly different (p=0.678). 
 
Figure 6e. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants practice according to the national cervical cancer guideline for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=97). 
Study participants that had adequate Pap screening practice according to the national cervical 
cancer guidelines at study enrolment had similar risk to become deceased or LTFU to study 
participants that did not have adequate Pap screening practice according to the national cervical 
cancer guidelines at study enrolment (p=0.897). 
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Figure 6f. Kaplan Meier estimates for all-cause attrition (death and LTFU) according to study 
participants practice according to the national HIV treatment guideline for study participants attending 
Themba Lethu clinic during the November 2009 to December 2012 period (n=100). 
 
Study participants that had adequate Pap screening practice according to the national HIV 
treatment guidelines at study enrolment had similar risk to become deceased or LTFU to study 
participants that did not have adequate Pap screening practice according to the national HIV 
treatment guidelines at study enrolment (p=0.890). 
3.4.2. Univariate analysis: analysis of attrition 
Cox proportional hazards models were fitted to identify predictors of attrition.  The crude 
hazards ratio (HR) was reported. 
Results from the univariate analysis indicated that having no education, part-time occupation, 
taking snuff, higher snuff taking frequency, lower baseline CD4 at HAART initiation, higher 
baseline ALT at HAART initiation, moderately high baseline Lactate levels at HAART , being 
initiated of HAART and non-negative baseline study Pap smear results at study enrolment were 
significantly associated with a greater risk of attrition. Table 11 shows hazard ratios for each 
covariate in the univariate analysis. 
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Global tests for proportional hazards assumptions based on Schoenfeld residuals were 
conducted after fitting univariate Cox models on all covariates. With the exception of 
nationality, all co-variates had p>0.05 indicating that the proportional hazards assumption was 
not violated. 
3.4.3. Multivariate analysis: analysis of attrition  
There was only one significant factor associated with attrition which was being initiated on 
HAART. Results from this analysis are provided in Table 11. 
Those that are initiated on HAART were 90% less likely to be deceased of LTFU than those 
that were not initiated on HAART (aOR=0.10, 95% CI 0.01-0.81). The global test for the 
overall model showed that the proportional hazard assumption had not been violated, p=0.684. 
Table 11: Analysis of all-cause attrition for study participants attending Themba Lethu clinic during the 
November 2009 to December 2012 period (n=1202). 
Factor 
All-cause Attrition (Deceased or LTFU) 
n (%) 
Alive and in Care 
1093 (90.93) 
Attrition 
(Deceased or LTFU) 
109 (9.07) 
Crude HR (95% CI) p-value Adjusted HR (95% CI) p-value 
Age groups: 18-29 149 (13.63) 12 (11.01) ref    
 30-39 485 (44.37) 61 (55.96) 0.88 (0.47-1.64) 0.687   
 40-49 368 (33.67) 29 (26.61) 1.00 (0.51-1.97) 0.996   
 50+ 91 (8.33) 7 (6.42) 0.86 (0.34-2.20) 0.757   
Race:  Black  1055 (96.52) 107 (98.17) ref       
     Other  38 (3.48) 2 (1.83) 1.63 (0.40-6.67) 0.499   
Nationality: South African  978 (90.64) 97 (89.81) ref       
                   Non-South African  101 (9.36) 11 (10.19) 0.63 (0.31-1.28) 0.200     
Marital Status: Single  592 (54.16) 66 (60.55) ref       
                    Married  202 (18.48) 12 (11.01) 0.76 (0.40-1.45) 0.411    
                    Cohabiting  152 (13.91) 18 (16.51) 0.95 (0.56-1.60) 0.842    
                    Divorced/ Separated 67 (6.13) 5 (4.59) 1.22 (0.49-3.04) 0.676    
                    Widow  80 (7.32) 8 (7.34) 0.93 (0.45-1.95) 0.854    
Education Level:  < Grade 10 214 (19.58) 15 (13.76) ref    ref   
                           Grade 10– Matric 756 (69.17) 78 (71.56) 1.25 (0.70-2.21) 0.452 2.16 (0.70-6.64) 0.181 
                           Tertiary  99 (9.06) 14 (12.84) 0.97 (0.46-2.06) 0.945 1.51 (0.53-2.51) 0.724 
                           None 24 (2.20) 2 (1.83) 4.22 (0.93-19.18) 0.063 2.51 (0.84-7.50) 0.600 
Currently Employed:  No 493 (45.11) 42 (38.53) ref       
                                Yes  600 (54.89) 67 (61.47) 0.93 (0.56-1.23) 0.348    
Occupation: Full-time 400 (67.91) 48 (71.64) ref    ref   
               Part-time 165 (28.01) 17 (25.37) 1.54 (0.87-2.73) 0.138 4.90 (0.69-34.80) 0.112 
               Self-Employed 24 (4.07) 2 (2.99) 0.71 (0.17-2.98) 0.643   
Currently Smoking:  No 1055 (96.52) 105 (96.33) ref       
                              Yes  38 (3.48) 4 (3.67) 1.82 (0.66-4.98) 0.244    
Smoking Frequency:   <5 per day 24 (72.73) 4 (100) ref       
                                      > 5 per day 9 (27.27) 0 (0) 3.82 (1.66-25.98) 0.999   
Currently taking snuff:  No  986 (90.21) 91 (83.49) ref    ref   
                                          Yes  107 (9.79) 18 (16.51) 0.67 (0.40-1.13) 0.132  0.25 (0.02-3.14) 0.283 
Snuff Frequency: <5 per day 85 (81.73) 13 (86.67) ref    ref   
                              > 5 per day 19 (18.27) 2 (13.33) 3.84 (0.74-19.94) 0.110 0.63 (0.03-14.63) 0.773 
Currently Drinking Alcohol: No  975 (89.20) 102 (93.58) ref       
                                                  Yes  118 (10.80) 7 (6.42) 0.96 (0.44-2.08) 0.920   
Baseline WHO staging:   I-II  512 (66.67) 46 (61.33) ref       
                                           III -IV 256 (33.33) 29 (38.67) 1.02 (0.64-1.63) 0.934    
Baseline BMI (kg/m2): Underweight (<18.5)    76 (9.34) 10 (12.50) ref       
                                       Normal (18.5-24.9)  434 (53.32) 45 (56.25) 0.99 (0.49-1.97) 0.968   
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                                Overweight (≥25)  304 )37.35) 25 (31.25) 1.22 (0.58-2.56) 0.604   
Baseline CD4 (cells/mm3): 0-50   171 (19.77) 22 (25.58) ref    ref   
                                             51-100  163 (18.84) 11 (12.79) 0.50 (0.23-1.12) 0.092  0.32 (0.02-4.23) 0.387 
                                      101-250  425 (49.13) 47 (54.65) 0.85 (0.51-1.41) 0.521 0.43 (0.03-6.70) 0.549 
                                      251-350  51 (5.90) 3 (3.49) 1.80 (0.53-6.10) 0.346 0.69 (0.01-33.81) 0.854 
                                      >350  55 (6.36) 3 (3.49) 2.12 (0.62-7.29) 0.233    
Baseline HIV viral load (copies/ml): <100 000 191 (76.40) 18 (75.00) ref       
                                                             ≥100 000 59 (23.60) 6 (25.00) 0.61 (0.24-1.58) 0.311   
Hemoglobin (g/dL): <8g/dL 42 (4.94) 4 (5.13) ref       
                                  ≥8g/dL 809 (95.06) 74 (94.87) 1.28 (0.46-3.52) 0.633    
AST (IU/L): <40 520 (73.76) 48 (69.57) ref     
                      >=40 185 (26.24) 21 (30.43) 1.21 (0.72-2.05) 0.476   
ALT (IU/L): <40 761 (87.27) 68 (82.93) ref   ref   
                      >=40    111 (12.73) 14 (17.07) 1.60 (0.89-2.88) 0.118 1.23 (0.46-3.29) 0.682 
Lactate levels (mmol/L): 0-2.4 - Normal 246 (53.60) 26 (56.52) ref  ref  
                                       2.5-4 – Moderately elevated 93 (20.26) 7 (15.22) 2.42 (0.96-6.05) 0.060 24.24 (0.71-122.84) 0.076 
                                       >4 – Severely elevated 120 (26.14) 13 (28.26) 0.98 (0.50-1.95) 0.962 0.50 (0.08-3.19) 0.467 
On HAART: No 43 (4.00) 1 (0.93) ref  ref  
                       Yes 1031 (96.00) 107 (99.07) 0.15 (0.02-1.14) 0.067 0.10 (0.01-0.81) 0.031 
HAART regimen*: 1a  569 (54.66) 52 (48.60) ref       
                    1b  96 (9.22) 11 (10.28) 1.54 (0.79-3.02) 0.206    
                    Other  376 (36.12) 44 (41.12) 1.37 (0.91-2.08) 0.136    
Baseline study Pap smear results: Negative  286 (26.31) 34 (33.66) ref   ref   
                              Moderate/Severe/ICC 801 (73.69) 67 (66.34) 1.44 (0.94-2.19 0.092 11.67 (1.30-104.64) 0.068 
Previous Pap smear results: Negative  493 (94.44) 30 (96.77) ref       
                                  Moderate/Severe/ICC 29 (5.56) 1 (3.23) 0.62 (0.08-4.60) 6.37    
Disease Development: Not Progressed 445 (65.93) 4 (66.67) ref    
                    Progressed 230 (34.07) 2 (33.33) 2.44 (0.01-0.52) 0.990   
Pap Awareness: Aware 789 (72.45) 60 (55.05) ref    
        Not aware 300 (27.55) 49 (44.95) 1.07 (0.73-1.58) 0.722   
HPV Awareness: Aware 200 (18.33) 18 (16.51) ref    
          Not aware 891 (81.67) 91 (83.49) 1.02 (0.62-1.70) 0.940   
Perceived Risk: Not Worried at All 245 (22.60) 35 (32.41) ref    
                            Somewhat Worried 236 (21.77) 14 (12.96) 0.98 (0.52-1.83) 0.951   
                            Very Worried 603 (55.63) 59 (54.63) 0.85 (0.56-1.29) 0.449   
Practice According to Cervical Cancer guidelines:       
                            Adequate 355 (37.61) 26 (26.80) ref    
       Not adequate 589 (62.39) 71 (73.20) 0.96 (0.61-1.52) 0.869   
Practice According to HIV treatment guidelines:       
       Adequate 284 (29.46) 20 (20.00) ref    
       Not adequate 680 (70.54) 80 (8000) 0.96 (0.59-1.58) 0.879   
*HAART regimens 1a – stavudine/ lamivudine/ efavirenz, (d4T / 3TC / EFV), 1b - stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP) 
 
In a sub-analysis, participants with a 12 month follow up visit’s characteristics and 
demographics were compared (by age, CD4 count, HAART status etc.) with study participants 
who did not have a 12 month follow up visit to determine if they are significantly different. 
This analysis showed that the two population groups were similar based on most of the 
characteristics assessed. However, the most notable difference noted was that the results of 
their baseline Pap screening results. Those that did not have a 12 month follow up visit 
conducted had the highest proportion of women with a severe baseline study Pap results 
(61.23%) compared to those that had a 12 month follow up study visit where most of the women 
had a moderate Pap screening results (50.07%).  
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CHAPTER 4: Discussion 
4.1. Introduction 
The study’s main objectives were to assess the awareness, perceived risk and practices related 
to cervical cancer and Pap screening among HIV-positive women in an urban HIV clinic in 
Johannesburg, South Africa. The findings of the study are discussed below according to each 
specific objective. 
4.2. Study participants’ baseline characteristics 
A majority of the women were Black (98.09%) and of South African nationality (90.86%). The 
majority (45.42%) of the women were in the 30-39 age group with  a mean age of 38.14 years 
(SD ±7.67) which is similar to a studies conducted in Kenya to assess awareness related to 
cervical cancer and Pap smear screening (46) and in Cameroon assessing HPV and cervical 
cancer prevention amongst health workers (47). Over 50% of the women were single with just 
over a third reporting to be in some sort of relationship with a partners; with 17.80% reporting 
that they were married and 14.14% reporting to be cohabiting with a partner.  
The study population were generally better educated than the overall South Africa female 
population. The overall South Africa population had on average 55.8% of the female population 
completing high school to Matric level education, while a higher proportion (11.9%) had no 
schooling at all compared to the study population (2.16%) (48). However, the overall South 
Africa female population had higher proportions (12.3%) of individuals that had tertiary level 
education (48). A majority of the participants in previous studies that did not target participants 
with technical jobs such as teachers or nurses had secondary school education (14, 49). 
The majority (96.88%) of the study participants were initiated on HAART which is a higher 
proportion than the larger TLC population which only had 74.31%. The study participants’ 
overall median CD4 count at HAART initiation was 138 cells/mm3 (IQR 63-205) which is 
lower than the recommended initiation CD4 count at the time which was less than 200 
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cells/mm3 (17). The current national HAART guideline recommendation has recently been 
changed to 500 cells/mm3 (50). The majority of the participant’s baseline viral load (VL) were 
missing (77.20%). VL was not required at baseline at HAART initiation as it was not the 
required standard of care according to the national HIV treatment guidelines (17, 18, 29). The 
majority (51.66%) of the study participants were initiated on HAART Regimen 1a – stavudine/ 
lamivudine/ efavirenz, (d4T / 3TC / EFV), with 107 (8.90%) initiated on Regimen 1b - 
stavudine/ lamivudine/ nevirapine (d4T / 3TC / NVP). Women who were on the NVP based 
regimen would mostly have reported their fertility intentions. Under the previous South Africa 
national HIV guidelines EFV was contraindicated for women who have reported their 
intentions to fall pregnant due to concerns related to the drug possibly negatively affecting the 
development of the pregnancy (45).  
Results when comparing the study population and the larger TLC cohort population indicated 
that there were no major difference between the two populations, only small differences were 
noted in most cases. However, it was noted that the study population was healthier at HAART 
initiation than the TLC cohort population. A higher proportion of the TLC cohort were initiated 
on HAART at a lower CD4 count, higher VL, and lower BMI compared to the study population. 
This could indicate there might be better health seeking behaviour from the study participant 
to be more likely to have been initiated on HAART, and to also be initiated on HAART when 
they’re healthier than their counterparts attending the same clinic. 
4.3. Awareness related to cervical cancer and Pap smear screening 
Several studies have consistently shown that lack of awareness and in particular lack of detailed 
knowledge about the disease and its prevention methods has led to an increase in incidence and 
prevalence of the disease (46, 51). 
Results from our study showed that a total of 857 (71.30%) participants reported to be aware 
of Pap smear screening. A study conducted amongst much younger (mean age 22 years SD 2.3 
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years) tertiary students in the Eastern Cape in South Africa showed similar results; 70% 
awareness of Pap smear screening amongst the study participants (52). We identified older age 
(>= 50 years), South African nationality and  higher than grade 10 education level as significant 
factors associated with being aware of Pap smear screening in our study. 
In a number of previous studies low literacy or low education has been consistently shown to 
be correlated to negative health behaviours and a cause for higher risk of morbidity and 
mortality (46, 53). Other studies have demonstrated that better education means better 
awareness and better knowledge regarding cervical cancer disease and screening (51, 54, 55). 
However, awareness did not necessarily translate to practice as screening history collected in 
our study indicated. This is a finding that has found in previous studies which indicates that 
practice is probably influenced by an array of factors differing in complexity, priority, and 
different contexts (47, 49, 51). All of the assortment of factors need to be better understood in 
order to implement adequate interventions to address this deficiency in HIV positive women 
seeking cervical cancer prevention services (47, 49, 51). 
Some of these studies theorised that older women were generally more concerned about getting 
cervical cancer disease more than younger women because cervical cancer was traditionally a 
disease that mostly affected older women (14, 56).  
Non-South Africans were shown to be less likely to be aware of Pap smear screening than South 
Africans. This could be accounted for by the fact that South Africa has one of the most 
progressive cervical cancer screening policies and programmes when compared to many 
countries in the Southern African region where over 90% of the non-South African participants 
originate from. This could also indicate the impact of the language barrier. Messaging related 
to cervical cancer disease prevention and treatment may be discussed by the health care workers 
and patients during the patient’s clinic visits during their care at the clinic, non-South African 
patients may not be getting the same quality of messaging as a result of a language barrier as 
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most likely health care workers at the clinic could not speak their language. Or it could be that 
because of the language barrier these non-South African study participants may not have 
understood the question clearly during the study interview. 
Remarkably, those that were initiated on HAART were found to be less likely to be aware of 
Pap smear screening than those that were not initiated on HAART. One would expect study 
participants that are initiated on HAART to have had more exposure to health messaging related 
to cervical cancer screening and have also had cervical screening conducted. The national HIV 
treatment guidelines recommend cervical cancer screening on diagnosis of HIV and if this 
screening test is negative then subsequent screening every three years, irrespective of HAART 
status (18). More needs to be done to provide adequate and appropriate patient education to 
patients in order to empower them with the knowledge to be able to seek these services (14, 47, 
51).  Moreover, it is also very important for health facilities to be adequately resourced to be 
able to offer these services (14, 47). 
None of the factors being assessed in the study proved to be significantly associated with the 
outcome in the analysis of awareness related to HPV. Nevertheless, lack of awareness and 
knowledge regarding HPV and its role in cervical cancer disease and its prevention is an 
important issue that has been identified in many studies. This further highlights the urgent need 
to address this through effective health education programmes (14, 29, 47).  
4.4.  Perceived risk related to cervical cancer and Pap screening 
Previous studies found that women’s perceived risk may negatively influence screening 
behaviours and lead to higher risk of morbidity and mortality (41, 42). In the analysis of 
perceived risk related to cervical cancer disease the significant factors identified were a tertiary 
education level, taking snuff and drinking alcohol. 
The results showed that compared to those with less than a grade 10 level education, having a 
tertiary level education increased the likelihood of study participants being more worried about 
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getting cervical cancer disease. In addition, study participants that took snuff and those that 
drank alcohol also were more worried about getting cervical cancer disease. Taking snuff is 
factor that has not been explored in previous studies that have evaluated the perceived risk 
related to cervical cancer especially amongst women from more rural areas where snuff use is 
more common than in urban areas. Long term use of tobacco has long been established as a 
risk factor to many cancers including cervical cancer (5). Perhaps the study participant’s 
perception of risk may have been influenced by knowledge that the taking snuff, which is a 
type of tobacco, is unhealthy and may contribute to poor health. The knowledge of their 
unhealthy habit may lead to having despondent views related to getting cervical cancer. In 
contrast, smoking cigarettes was not associated to perceived risk of related to cervical cancer. 
However, snuff use was more prevalent in our study population than smoking which might be 
because snuff is much cheaper than cigarettes. 
In our study a majority (55.54%) of the participants reported to be very worried about getting 
cervical cancer. Women may have a fatalistic view of the disease outcomes and not seek 
screening services as they may see no hope of any positive outcomes should they have the 
disease (14, 46, 57). This state of mind can be further exacerbated by use of alcohol, one of the 
factors found to be associated with perceived risk related getting cervical cancer disease. On 
the other hand, the belief that they are not susceptible to the disease may lead women to forgo 
screening thereby missing on the chance to detect and treat the disease appropriately (39). In 
both cases lack of awareness and knowledge regarding the disease and its prevention was seen 
as important factors influencing the women’s perception regarding their risk related to the 
disease (39, 57).  
More needs to be done towards ensuring that women have detailed and correct knowledge 
regarding cervical cancer, its related risk factors and its methods of prevention. This will ensure 
that their perception of risk related to the disease is more accurate, and will hopefully positively 
influence their screening practices (14, 46). 
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4.5. Practice related to Pap smear screening 
Although our study population may have high rates of awareness related to Pap smear 
screening, many studies have shown that awareness doesn’t necessarily translate to adequate 
practice related to seeking prevention services (39, 49, 58). A majority of the women in the 
study had inadequate screening practices. Only 36.46% women had adequate practice 
according to the national cervical cancer guidelines, and even fewer (28.57%) had adequate 
practice according to the national HIV treatment guidelines.  
The factors age, marital status, being initiated on HAART and occupation were found to have 
significant association with Pap screening practice according to the national cervical cancer 
guideline. Our results showed that women in the 30-39 age category at enrolment in the study 
had increased odds of adequate practice related to cervical cancer screening when compared to 
younger women. This could be because cervical cancer was traditionally a disease that mostly 
affected older women, and according to the national cervical cancer guidelines this age group 
would have been targeted for screening as part of the national screening programme (14, 17, 
56).  
Those that were self-employed were more likely to have adequate practice according to the 
national cervical cancer guidelines than those with full time employment. These results were 
similar to those in a study in Zimbabwe assessing knowledge, attitudes, and demographic 
factors influencing cervical cancer screening behaviour (59). This study showed that women 
who were financially independent were more likely to access cervical cancer screening than 
those that were financially dependent on their husbands (59). Previous studies have shown that 
women from higher resource settings demonstrated better health seeking behaviour, and self-
employed women may be seen to be of a better economic status than their unemployed 
counterparts as they may be more economically active and economically independent (55, 57, 
59). Results also showed that women who reported to be cohabiting with a partner were less 
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likely to have adequate practice according to the national cervical cancer guidelines compared 
to their single counterparts. They may be facing the challenge of being economically depended 
of their partners and thus they would be less likely to access screening services, and this also 
reduces their opportunity to be exposed to health messaging related to cervical cancer 
screening. 
Those that were initiated on HAART were found to be less likely to have adequate Pap 
screening practices according to the national cervical cancer guidelines than those that were not 
initiated on HAART. This finding is concerning since patients that were initiated on HAART 
should’ve had more exposure to health messaging including the importance of cervical cancer 
screening, and they should have had screening conducted on treatment initiations as 
recommended in the national HIV treatment guidelines. In addition, all the women included in 
the analysis were over the age of 30 years and according to the national cervical cancer 
guidelines they would have been targeted for screening according to the cervical cancer 
guideline as part of the national screening programme. More needs to be done to ensure services 
are adequately available to patients; ensuring that health practitioners have adequate skills, 
knowledge, and resources to be able to implement screening programmes as per guidelines. 
However, patients also need to be provided with appropriate information, education and 
communication to gain the knowledge and empowerment to be able to seek these services (14, 
47, 51).  
In the analysis of practice related to Pap smear testing none of the factors proved to be 
significantly associated with the practice according to the national HIV treatment guidelines.  
In a cross sectional study assessing awareness of HPV and cervical cancer prevention amongst 
Cameroonian health workers it was found that although a high proportion of the study 
participants were aware of cervical cancer and Pap smear screening only 40% had adequate 
screening practice (47). Similar results were found by Mutyaba et al in their assessment of 
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knowledge, attitude and screening practices on cervical cancer screening among medical 
workers in Mulago Hospital in Uganda 39). These are concerning results especially considering 
that these were educated healthcare workers with adequate knowledge regarding the disease 
and its prevention, and had access to free screening at their place of work (14, 39, 47). They 
should be at the forefront of opportunistic screening of women they care for, and if they are not 
getting screened themselves then chances are this will have a negative effect on them screening 
their patients or referring them appropriately for screening (14, 39, 47). Wellensiek et al found 
that most patients who participated in their study to evaluate knowledge of cervical cancer 
screening and use of cervical screening facilities among women from various socioeconomic 
backgrounds in Durban, resided within a 12-kilometer radius of a facility that either provided 
or could potentially provide screening (55). Despite this the study found very poor Pap smear 
screening practice among these patients, only 27.3% of the patients reported having had a Pap 
smear test. One of the factors that was reported to be affecting this was the role of health 
providers. They did not provide adequate information to patients regarding the need for cervical 
screening, and its benefit (55).  
Results from this study and previous studies highlight the fact that practice related to cervical 
cancer screening is more complex and there is an urgent need to better understand all the factors 
affecting women’s cervical screening practices (39, 47, 55, ). Current data for South Africa 
indicate that a large number of women remain unscreened (58). This and data from other 
countries shows that good screening policies and availability of screening facilities  does not 
lead to the reduction in morbidity and mortality related to cervical cancer disease if uptake of 
screening services is not adequate. (39, 57, 58 ). This calls for more innovative health education 
strategies which may include nationwide campaigns that use local languages, leveraging local 
community groups that women have regular contact with and that have influence over them 
such as churches and burial societies or groups (51). Concerted effort is also needed in targeting 
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husbands and partners of these women as they also have influence in the women’s health 
seeking practices including seeking Pap screening services (59, 60). 
4.6. Participant’s baseline study Pap smear results 
Out of the 688 (57.24%) study participants that reported to have ever had Pap smear screening 
before the study a majority, 523 (94.58%), reported that their previous Pap smear test before 
participating in the study were negative. Results were self-reported in most cases, and close to 
20% of the participants did not have results reported from their previous screening. They either 
could not remember what the results were, or they never collected their results. Both factors 
have been observed in other studies that involved details of participants’ screening history and 
results from previous screening (46, 55). Similar findings were noted in a study by Wellensiek 
et al conducted amongst women from various socioeconomic backgrounds in Durban, 
KwaZulu Natal, South Africa (55). The study assessed knowledge of cervical cancer screening 
and use of screening facilities by study participants (55). Results from this study indicated that 
some women reported not being informed what the purpose of the screening test was in their 
previous Pap screening encounters (55). A very concerning finding as this does not benefit 
women actively participating and taking responsibility in their own health care. Taking 
responsibility for their own health care is something to be encouraged as it is hoped that it can 
positively contribute to the women’s health seeking behaviour including their uptake of 
prevention screening services like cervical cancer screening. 
Only one (0.18%) of the women reported that they had a severe Pap smear results in their 
previous Pap smear test before the study, and 29 (5.24%) had Pap smear results classified as 
moderate. We did not confirm the self-reported results against previous laboratory results so it 
was not possible to determine if women could accurately report/recall their previous Pap smear 
results. It has been shown that self-reports often overestimate participation in cervical cancer 
screening (46, 55). Ombech et al reported that after examining medical records to confirm 
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reported screening practices, most women overestimated the number of smears taken and how 
recent the screening was conducted (46). 
Out of the 1198 study participants who had a result reported from their baseline study Pap 
smear two (0.17%) cases of ICC were reported. A total 321 (26.79%) participants had negative 
baseline study Pap smear results. A majority (39.57%) of the results reported were moderate 
while 33.47% of the participant’s results were classified as severe, meaning that their Pap smear 
results were HSIL, ASC-H, CIN II or CIN III. These are a huge contrast to the results reported 
from previous Pap smear test before the study. Most of the previous Pap results were self-
reported and not sourced from participants’ medical records therefore there could be some 
discrepancies with what the patients reported to what the actual results were. In addition, there 
could have been some progression of dysplasia from their previous Pap smear. These rates of 
higher grade (severe) Pap smear results are much higher than previous studies, including a 
study conducted in the same clinic in 2010 on a different cohort of women (29). In that study 
the prevalence of severe results was almost half of what is reported in our study results (29). 
Of the women reported with severe results in our study 15% were from participants in the 18-
29 age group. Interestingly, age was not associated with severity of baseline Pap results in our 
study. It is important to note that it has been found that age and dysplasia correlate in HIV 
negative populations, however HIV positive status has now been shown to be a more important 
risk factor to dysplasia in HIV positive women than age. This has been attributed to the HIV-
related immunosuppression which may impact disease development and progression (9, 10, 
29). Research has consistently shown more women are presenting with dysplasia younger 
which has been linked to HIV infection (16, 28). The higher proportion of severe Pap results 
could be linked to several factors including: i) the study cohort is HIV positive (33), ii) they 
have a previous history of immune suppression (7), and iii) because they have been initiated on 
HAART, they are getting to live longer (7, 29).  
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These are all reasons which previous studies have listed for HIV positive women having a 
higher cervical cancer rate, as well as more severe, and more persistent cervical cancer (7, 29). 
This further highlights the importance of strengthening cervical cancer screening practices 
amongst all at risk women, especially HIV positive women. 
4.7. 12 month follow up outcomes 
4.7.1. Disease progression 
The majority of the study participants included in the analysis (65.93%) did not have any 
disease progression noted; their results indicate that either their results stayed the same as their 
baseline results from their Pap smear screening from the preceding 12 months or that they had 
improved. It is important to note that the group that experienced disease progression had a 
slightly lower CD4 count at HAART initiation, a factor that indicates a history of immune 
suppression which could possibly have influenced this group’s noted disease progression. 
Findings from other studies, including a study conducted in a different cohort of women in the 
same clinic as our study found that the risk of cervical abnormalities was higher with lower 
CD4 count (10, 29). These findings highlights the importance of cervical screening of HIV 
positive women as directed by the national cervical cancer screening guidelines  
A sub-analysis (Appendix 2a) comparing characteristics and demographics of participants with 
a 12 month follow up visit’s and those that did not have a 12 month follow up visit conducted 
(by age, CD4 count, HAART status etc.) showed that the two population groups were similar 
based on most of the characteristics assessed. However, the most notable difference noted was 
that the results of their baseline Pap screening results. Those that did not have a 12 month 
follow up visit conducted had the highest proportion of women with a severe baseline study 
Pap results (61.23%) compared to those that had a 12 month follow up study visit where most 
of the women had a moderate Pap screening results (50.07%). It was found that those that were 
treated off study (77.43%), died (42.86%), and those that were unable to treated (70.59%) had 
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the highest proportion of women with a severe baseline Pap screening results at study 
enrolment. 
Association of disease progression and awareness, perceived risk and practices related to Pap 
smear testing was assessed. Disease progression had significant association with having a non-
negative baseline study Pap smear at study enrolment. Compared to those that had a negative 
baseline study Pap smear those that had a moderate to severe baseline study Pap smear were 
less likely to have disease progression at their 12 month Pap smear screening. This is probably 
because they would have had a treatment intervention based on their baseline study Pap result 
and would therefore likely not have disease progression at a follow up screening. This is 
evidence of how screening can be an important prevention tool in the fight against the 
development of cervical cancer disease. 
 
4.7.2. Analysis of all-cause attrition  
Of the 42.76% attrition experienced for the 12 month follow up study visit, seven (1.36%) can 
be attributed to death, and 102 (19.84%) due to lost to follow up. The majority of the 319 
(62.06%) participants who did not have a 12 month study visit were treated off study as a result 
of the severity of their baseline study Pap results. These individuals were either referred to 
VICAR2 for treatment or were treated off study. A total of 46 (8.95%) participants became 
pregnant thereby making them no longer eligible to be in the study. A further assessment was 
conducted to assess association between awareness, perceived risk and practices related to 
cervical cancer screening, disease progression, and being treated off study. The results from 
this assessment found significant association between disease progression and being treated off 
study. Where those that were treated off study were less likely to have disease progression 
noted in their 12 month follow up Pap screening results. This could be because there would 
have been an intervention based on the baseline study Pap screening conducted at enrolment in 
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the study, the intervention would expectantly improve patient prognosis as a result of the 
cervical cancer related disease. 
A total of seven (1.36%) withdrew their consent to be part of the study.  A further 15 (2.92%) 
participants were unable to be treated, and therefore did make up part of the 12 month follow 
up study visit data set. All in all, the study experienced over a third attrition with most resulting 
from lost to follow up. If this is examined even further only 9.1% of the original study 
population were truly lost (deceased or lost to follow up), the rest of the attrition was as a result 
of the study protocol requirements for 1) referral to treatment interventions where they were 
needed based of severe baseline Pap results, 2) women falling pregnant and study protocol 
requiring they no longer participate in the study as they no longer met criteria.  The reason why 
most of the study participants could be accounted for by the end of the study could be that the 
study is clinic-based and the clinic is where the participants normally attend for their HIV care 
and treatment services and because the study was undertaken in an urban hospital. The clinic 
may be more accessible because of convenience of direct public transport routes. The study 
itself was well resourced to be better able to follow up with patients who miss appointments. 
The seven deaths reported in the study equate to a proportion of 0.58% study participants 
becoming deceased by the end of the study. All study participants’ deaths occurred in the 30-
39 years age group. Survival analysis to analyse those that were deceased by the end of the 
study did not yield meaningful results as the sample size was small and therefore did not have 
sufficient power. The study was an analysis of secondary data and we therefore did not have 
control over the sample size determination. Further analysis was conducted to examine all-
cause attrition. The number of study participants that were alive and in HIV care were compared 
to those that were no longer alive and in HIV care (those that died or were lost to follow up), 
in relation to participants’ awareness, perceived risk and practice related to Pap smear testing 
and baseline covariate, namely study participants’ baseline socio-demographic and clinical 
characteristic at HAART initiation.  
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The only significant factor noted in this adjusted model which was being initiated on HAART. 
Those that were initiated on HAART were less likely to be deceased or LTFU than those that 
were not initiated on HAART. This is understandable as patients initiated on HAART would’ve 
been expected to have better clinical outcomes. They would be under clinical care at the clinic 
meaning they would have regular contact with health care providers which may account for 
them being less likely to be lost to follow up or deceased. 
4.8. Study limitations 
4.8.1. Information bias 
Some of the questions on the questionnaire are of a personal nature and some individuals may 
have been too embarrassed to answer them truthful. Information bias was minimised by the fact 
that the interviewers received standard training and had a standard operating procedure (SOP) 
for conducting interviews. In addition, interviewers are fluent in the local languages therefore 
the participants were in most cases interviewed in their own languages.  
Recall bias might also be a factor regarding medical history. Respondents that were previously 
diagnosed with a severe form of the disease might have remembered the diagnosis more 
accurately. They would have had invasive procedures conducted as compared to those who had 
a negative Pap smear or had only minor indications of the disease. In addition, these 
respondents might also be reluctant to disclose previous diagnosis because of fear of 
stigmatization.  
Another limitation was missing data for some of the study variables, and no follow up data for 
the study participants without 12 months follow up study visit could also have added some bias 
to the analysis. 
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In addition, there were a small number of study participants (37 or 3.12%) that were not 
initiated on HAART and therefore did not have baseline clinical data to be able to be assessed 
in the analysis that involved analysing clinical data. 
There is also a possibility of selection bias as respondents selected for the study are HIV-
positive and the general population (HIV-negative patients) differ in terms of general health 
status. As a result the study will not be able to be generalised to the general population as 
participants from this study differ systematically from the general population. 
Selection bias may exist in this study as participants enrol in the study either because they are 
unwell (lower CD4 cell count) or because their health care provider is particularly worried 
about the exposure. Because they are seeking care and HAART treatment, these patients may 
be healthier than their HIV-positive counterparts who are eligible for HAART but are not on 
HAART and are not seeking care and treatment (54). At the same time this group of patients 
(those enrolled in the study) may not be as healthy as their counterpart who are not yet initiated 
on HAART as their CD4 count would have had to drop to a certain level or they would have 
had to have other AIDS defining illnesses in order to be initiated on HAART (14). To minimise 
this participants were compared to female patients (by age, CD4 count, HAART status etc.) 
enrolled in the same clinic for HIV care and treatment but are not enrolled in the study, and we 
assessed whether women in the study differ significantly from those that did not enrol in the 
study. Results indicated that there were no major difference between the two populations, only 
slight differences were noted in most cases. 
4.8.2. Generalisability 
Themba Lethu Clinic is an urban Comprehensive Care Treatment and Management (CCMT) 
site which is located in a tertiary hospital. Therefore generalizability of our study findings 
beyond the study population may be limited as Themba Lethu clinic is different from many 
non-tertiary, smaller, or rural facilities found throughout the country.  
72 
 
4.8.3. Confounding  
Information of possible confounders, for instance socio-demographic data such as age 
education level, employment status, smoking status, and alcohol consumption was collected 
during the data collection stage of the study, and they were adjusted for during the statistical 
analysis stage of the study using multivariate analysis. This method assisted to control for the 
confounding effect of several factors at the same time. 
However, unmeasured confounding could still be a limitation; variables which could’ve been 
potential confounders that were not collected as part of the study or routine patient management 
data could add some bias. 
In addition, as part of the statistical analysis interaction terms were created between variables 
found to be significant in the multivariable model. These interaction terms were fitted into the 
multivariable model to assess statistical significance however there was no significant 
relationship in any of the models. 
 
4.9. Conclusion 
Results for our study showed high levels of Pap smear screening awareness amongst the study 
participants. However, low levels of Pap screening uptake was observed for study participants. 
These results and results in previous studies demonstrate that awareness is only the first hurdle 
in the challenges related to cervical cancer prevention and treatment. Adequate practice is the 
factor that will have the most positive influence on the disease morbidity and mortality. 
Although South Africa has national programmes for cervical cancer screening and HIV 
treatment this does not necessarily translate to adequate implementation in terms of provision 
of services and also clients adequately seeking the services according to policy. This highlights 
that more research needs to be done into effective health education programmes to address the 
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gaps in adequate screening practice. These efforts should not only target the clients but also the 
health providers as they also have an important role to play in improving awareness, knowledge 
and practices related to cervical cancer and Pap smear screening amongst their clients. These 
efforts will hopefully contribute positively in positively influence screening behaviour and thus 
improve disease outcomes. 
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6. Appendices 
Appendix 1a: Study participant socio-demographic characteristics stratified by study outcomes 
 
Total (n= 1202) 
Awareness about Pap Smears 
n (%) 
Awareness about HPV 
n (%) 
Perceived Risk regarding cervical cancer 
n (%) 
Practice according to 
National cervical cancer 
guidelines 
n (%) 
Practice according to HIV 
guidelines 
n (%) 
Aware 
857 (71.30) 
Not aware 
345 (28.70) 
Aware  
218 (18.15) 
Not aware 
 983 (81.85) 
Very Worried 
662 (55.54) 
Somewhat 
Worried  
250 (20.97) 
Not Worried 
at all 
280 (23.49) 
Adequate 
 381 (36.46) 
Not Adequate 
664 (63.54) 
Adequate 
304 (28.57) 
Not 
Adequate 
760 (71.43) 
Age (Mean, ± SD)  38.4 (7.80) 37.37 (7.29) 37.42 (7.14) 38.31 (7.78) 37.47 (7.61) 38.93 (7.69) 38.94 (7.65) 36.97 (5.23) 41.53 (6.92) 39.82 (8.06) 37.73 (7.37) 
Age groups: 18-29 106 (12.37) 55 (15.94) 25 (11.47) 136 (13.84) 101 (15.26) 24 (9.60) 35 (12.50) - - 28 (9.21) 107 (14.08) 
  30-39 389 (45.39) 157 (45.51) 110 (50.46) 435 (44.25) 317 (47.89) 112 (44.80) 112 (40.00) 301 (79.00) 245 (37.12) 125 (41.12) 353 (46.45) 
  40-49 284 (33.14) 113 (32.75) 73 (33.49) 324 (32.96) 194 (29.31) 93 (37.20) 107 (38.21) 70 (18.37) 327 (49.55) 114 (37.50) 250 (32.89) 
  50+ 78 (9.10) 21 (3.02) 10 (4.59) 88 (8.95) 50 (7.55) 21 (8.40) 26 (9.29) 10 (2.62) 88 (13.33) 37 (12.17) 50 (6.58) 
Race:            Black  836 (97.55) 343 (99.42) 212 (97.25) 966 (98.27) 648 (97.89) 246 (98.40) 275 (98.21) 369 (96.85) 650 (98.48) 295 (97.04) 747 (98.29) 
                      Other  21 (2.45) 2 (0.58) 6 (2.75) 17 (1.73) 14 (2.11) 4 (1.60) 5 (1.79) 12 (3.15) 10 (1.52) 9 (2.96) 13 (1.71) 
Nationality:  South African  778 (92.29) 295 (87.28) 195 (90.70) 877 (90.88) 592 (91.08) 223 (91.02) 250 (90.58) 345 (91.76) 596 (92.12) 279 (91.78) 692 (91.17) 
              Non-South African  65 (7.71) 43 (12.72) 20 (9.30) 88 (9.12) 58 (8.92) 22 (8.98) 26 (9.42) 31 (8.24) 51 (7.88) 25 (8.22) 67 (8.83) 
Marital Status: Single  468 (54.61) 190 (55.07) 116 (53.21) 541 (55.04) 366 (55.29) 132 (52.80) 154 (55.00) 208 (54.59) 337 (51.06) 168 (55.26) 425 (55.92) 
            Married  155 (18.09) 59 (17.10) 44 (20.18) 170 (17.29) 111 (16.77) 43 (17.20) 59 (21.07) 86 (22.57) 115 (17.42) 57 (18.75) 131 (17.24) 
            Cohabiting  112 (13.07) 58 (16.81) 27 (12.39) 143 (14.55) 104 (15.71) 37 (14.80) 29 (10.36) 42 (11.02) 95 (14.39) 33 (10.86) 112 (14.74) 
            Divorced/ Separated  57 (6.65) 15 (4.35) 16 (7.34) 56 (5.70) 41 (6.19) 15 (6.00) 13 (4.64) 24 (6.30) 47 (7.12) 23 (7.57) 39 (5.13) 
Widow  65 (7.58) 23 (6.67) 15 (6.88) 73 (7.43) 40 (6.04) 23 (9.20) 25 (8.93) 21 (5.51) 66 (10.00) 23 (7.57) 53 (6.97) 
Education: < Grade 10 138 (16.10) 91 (26.38) 17 (7.80) 212 (21.57) 104 (15.71) 56 (22.40) 65 (23.21) 54 (14.17) 161 (24.39) 68 (22.37) 135 (17.76) 
Grade 10 – Matric  615 (71.76) 219 (63.48) 172 (78.90) 661 (67.24) 472 (71.30) 172 (68.80) 186 (66.43) 267 (70.08) 448 (67.88) 190 (62.50) 551 (72.50) 
Tertiary  89 (10.39) 24 (6.96) 28 (12.84) 85 (8.65) 76 (11.48) 16 (6.40) 20 (7.14) 57 (14.96) 33 (5.00) 39 (12.83) 56 (7.37) 
None  15 (1.75) 11 (3.19) 1 (0.46) 25 (2.54) 10 (1.51) 6 (2.40) 9 (3.21) 3 (0.79) 18 (2.73) 7 (2.30) 18 (2.37) 
Currently Employed : Yes  481 (56.13) 198 (57.39) 119 (54.59) 560 (56.97) 361 (54.53) 140 (56.00) 173 (61.79) 210 (55.12) 382 (57.88) 174 (57.24) 425 (55.92) 
     No  376 (43.87) 147 (42.61) 99 (45.41) 423 (43.03) 301 (45.47) 110 (44.00) 107 (38.21) 171 (44.88) 278 (42.12) 130 (42.76) 335 (44.08) 
Occupation: Full-time 314 (65.28) 134 (67.68) 72 (60.50) 376 (67.14) 240 (66.48) 81 (57.86) 124 (71.68) 137 (65.24) 260 (68.06) 121 (69.54) 271 (63.76) 
                Part-time 129 (26.82) 53 (26.77) 33 (27.73) 149 (26.61) 91 (25.21) 48 (34.29) 41 (23.70) 56 (26.67) 100 (26.18) 39 (22.41) 127 (29.88) 
                Self-Employed 21 (4.37) 5 (2.53) 8 (6.72) 18 (3.21) 18 (4.99) 5 (3.57) 3 (1.73) 12 (5.71) 10 (2.62) 8 (4.60) 12 (2.82) 
                Unknown Occupation 8 (1.66) 3 (1.52) 2 (1.68) 9 (1.61) 4 (1.11) 4 (2.86) 3 (1.73) 1 (0.48) 8 (2.09) 5 (2.87) 6 (1.41) 
                Student 3 (0.62) 3 (1.52) 3 (2.52) 3 (0.54) 4 (1.11) 1 (0.71) 1 (0.58) 2 (0.95) 0 (0) 0 (0) 4 (0.94) 
                State grant 6 (1.25) 0 (0) 1 (0.84) 5 (0.89) 4 (1.11) 1 (0.71) 1 (0.58) 2 (0.95) 4 (1.05) 1 (0.57) 5 (1.18) 
Currently Smoking: Yes  32 (3.73) 10 (2.90) 10 (4.59) 32 (3.26) 25 (3.78) 10 (4.00) 7 (2.50) 12 (3.15) 20 (3.03) 14 (4.61) 25 (3.29)  
               No  825 (96.27) 335 (97.10) 208 (95.41) 951 (96.74) 637 (96.22) 240 (96.00) 273 (97.50) 369 (96.85) 640 (96.97) 290 (95.39) 735 (96.71) 
Smoking Frequency: <5 per day 21 (75.00) 7 (77.78) 4 (50.00) 24 (82.76) 15 (68.18) 8 (100.00) 5 (71.43) 7 (63.64) 14 (82.35) 12 (85.71) 15 (68.18) 
               > 5 per day 7 (25.00) 2 (22.22) 4 (50.00) 5 (17.24) 7 (31.82) 0 (0) 2 (28.57) 4 (36.36) 3 (17.65) 2 (14.29) 7 (31.82) 
Currently taking snuff: Yes  76 (8.87) 49 (14.20) 19 (8.72) 106 (10.78) 60 (9.06) 24 (9.60) 41 (14.64) 40 (10.50) 76 (11.52)  25 (8.22) 93 (12.24) 
       No  781 (91.13) 296 (85.80) 199 (91.28) 877 (89.22) 602 (90.94) 226 (90.40) 239 (85.36) 341 (89.50) 584 (88.48) 279 (91.78) 667 (87.76) 
Snuff Frequency: <5 per day 61 (82.43) 37 (82.22) 15 (88.24) 83 (81.37) 49 (85.96) 20 (86.96) 29 (74.36) 30 (76.92) 62 (86.11) 23  (92.00) 70 (80.46) 
                            > 5 per day 13 (17.57) 8 (17.78) 2 (11.76) 19 (18.63) 8 (4.04) 3 (13.04) 10 (25.64) 9 (23.08) 10 (13.89) 2  (8.00) 17 (19.54) 
Currently Drinking Alcohol: Yes                         103 (12.02) 22 (6.38) 33 (15.14) 92 (9.36) 76 (11.48) 30 (12.00) 18 (6.43) 53 (13.91) 49 (7.42) 39 (12.83) 67 (8.82) 
          No  754 (87.98) 323 (93.62) 185 (84.86) 891 (90.64) 586 (88.52) 220 (88.00) 262 (93.57) 328 (86.09) 611 (92.58) 265 (87.17) 693 (91.18) 
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Appendix 1b: Study participants baseline clinical characteristic at HAART initiation stratified by study outcomes 
 
Total (n= 1202) Awareness about Pap Smears n (%) 
Awareness about HPV 
n (%) 
Perceived Risk regarding cervical cancer 
n (%) 
Practice according to national 
cervical cancer guidelines 
n (%) 
Practice according to HIV 
treatment guidelines 
n (%) 
Aware 
857 (71.30) 
Not aware 
345 (28.70) 
Aware  
218 (18.15) 
Not aware 
 983 (81.85) 
Very Worried 
662 (55.54) 
Somewhat 
Worried  
250 (20.97) 
Not Worried 
at all 
280 (23.49) 
Adequate 
381 (36.46) 
Not Adequate 
664 (63.54) 
Adequate 
304 (28.57) 
Not Adequate  
760  (71.43) 
Baseline WHO staging:  I-II  406 (67.44) 152 (63.07) 103 (69.13) 455 (65.66) 291 (64.38) 118 (68.60) 145 (68.08) 185 (68.01) 303 (65.87) 162 (68.94) 354 (63.44) 
                                    III -IV 196 (32.56) 89 (36.93) 46 (30.87) 238 (34.34) 161 (35.62) 54 (31.40) 68 (31.92) 87 (31.99) 157 (34.13) 73 (31.06) 204 (36.56) 
Baseline BMI (kg/m2) (Med, IQR) 23.32 (20.93-27.14) 23.38 (20.15-26.71 23.58 (20.12-28.39) 23.30 (20.76-26.85) 23.38 (20.42-26.98) 22.90 (20.85-26.76) 23.67 (20.78-27.34) 23.59 (21.30-27.87) 23.53 (20.74-27.30) 23.82 (21.39-28.40) 23.07 (20.36-26.71) 
Underweight (<18.5)  58 (9.22) 28 (10.57) 19 (11.80) 67 (9.15) 48 (10.11) 19 (10.11) 19 (8.52) 20 (7.25) 47 (9.40) 18 (7.38) 63 (10.64) 
Normal (18.5-24.9)  341 (54.21) 138 (52.08) 78 (48.45) 401 (54.78) 258 (54.32) 103 (54.79) 115 (51.57) 153 (55.43) 256 (51.20) 125 (51.23) 323 (54.56) 
Overweight (≥25)  230 (36.57) 99 (37.36) 64 (39.75) 264 (36.07) 169 (35.58) 66 (35.11) 89 (39.91) 103 (37.32) 197 (39.40) 101 (41.39) 206 (34.80) 
Baseline CD4 (cells/mm3) (Med, IQR) 141 (63-205) 120.5 (56.5-203.5) 136.5 (57-205) 133.5 (63-204) 132 (61-201) 131 (63-204) 151 (64-223) 132 (59.5-205) 131 (62-204) 137.5 (63-206) 132 (57.5-200) 
0-50   132 (20.59) 59 (22.01) 35 (22.15) 156 (20.80) 106 (21.59) 38 (20.43) 46 (20.44) 58 (20.71) 109 (21.33) 49 (19.60) 134 (22.19) 
51-100  115 (17.94) 52 (19.40) 27 (17.09) 140 (18.67) 89 (18.13) 36 (19.35) 37 (16.44) 60 (21.43) 92 (18.00) 43 (17.20) 113 (18.71) 
101-250  317 (49.45) 132 (49.25) 78 (49.37) 370 (49.33) 243 (49.49) 95 (51.08) 110 (48.89) 126 (45.00) 255 (49.90) 132 (52.80) 291 (48.18) 
251-350  35 (5.46) 12 (4.48) 11 (6.96) 36 (4.80) 22 (4.48) 11 (5.91) 14 (6.22) 14 (5.00) 28 (5.48) 13 (5.20) 30 (4.97) 
>350  42 (6.55) 13 (4.85) 7 (4.43) 48 (6.40) 31 (6.31) 6 (3.23) 18 (8.00) 22 (7.86) 27 (5.28) 13 (5.20) 36 (5.96) 
Baseline HIV VL (copies/mL) (Med,IQR) 17000 (176-94000) 6700 (49-83000) 42007 (189-170000) 12200 (68.5-78000) 12700 (58-78000) 39000 (274-170000) 6700 (107-89824) 11500 (84.5-74500) 23500 (62-114739) 9550 (229.5-62000) 17000 (91-111000) 
<100 000  152 (76.00) 52 (77.61) 32 (68.09) 172 (78.18) 113 (78.47) 30 (63.83) 60 (80.00) 72 (81.82) 110 (73.33) 57 (83.82) 132 (73.33) 
≥100 000  48 (24.00) 15 (22.39) 15 (31.91) 48 (21.82) 31 (21.53) 17 (36.17) 15 (20.00) 16 (18.18) 40 (26.67) 11 (16.18) 48 (26.67) 
Haemoglobin (g/dL) (Med, IQR) 11.6 (10.35-12.9) 11.6 (10.1-12.6) 11.7 (10.7-12.7) 11.6 (10.2-12.8) 11.6 (10.1-12.8) 11.5 (10.3-12.9) 11.7 (10.4-12.8) 11.6 (10.6-12.9) 11.6 (10.2-12.7) 11.6 (10.5-12.9) 11.6 (10.2-12.8) 
<8g/dL  33 (5.03) 13 (4.76) 5 (3.07) 41 (5.36) 29 (5.78) 7 (3.83) 10 (4.24) 15 (5.19) 19 (3.67) 14 (5.51) 30 (4.89) 
≥8g/dL  623 (94.97) 260 (95.24) 158 (96.93) 724 (94.64) 473 (94.22) 176 (96.17) 226 (95.76) 274 (94.81) 499 (96.33) 240 (94.49) 583 (95.11) 
AST (IU/L) (Med, IQR)  30 (24-41) 30 (24-39) 30 (23-41) 30 (24-40) 30 (24-40) 30 (24-42) 30 (24-40) 30 (24-42) 30 (24-39) 30 (24-41) 30 (24-40) 
       <40 405 (72.32) 159 (75.71) 97 (74.62) 466 (72.93) 318 (74.47) 97 (69.29) 146 (74.11) 174 (70.73) 319 (75.06) 140 (72.54) 390 (73.03) 
       >=40 155 (27.68) 51 (24.29) 33 (25.38) 173 (27.07) 109 (25.53) 43 (30.71) 51 (25.89) 72 (29.27) 106 (24.94) 53 (27.46) 144 (26.97) 
ALT (IU/L) (Med, IQR) 22 (16-32) 20 (14-29) 20 (16-32) 21 (15-31) 21 (15-31) 21 (16-30) 22 (15-31) 23 (16-33) 21 (15-30) 23 (16-33) 21 (15-31) 
       <40 578 (86.92) 240 (86.96) 140 (83.83) 677 (87.58) 452 (88.11) 162 (87.57) 197 (83.83) 238 (82.93) 469 (88.99) 214 (84.58) 548 (87.96) 
       >=40 87 (13.08) 36 (13.04) 27 (16.17) 96  (12.42) 61 (11.89) 23 (12.43) 38 (16.17) 49 (17.07) 58 (11.01) 39 (15.42) 75 (12.04) 
Lactate levels (mmol/L)  (Med, IQR) 2.2 (1.50-3.93) 2.45 (1.54-5.32) 2.09 (1.49-4.01) 2.3 (1.52-4.4) 2.34 (1.53-4.5) 2.28 (1.51-3.77) 2.07 (1.49-3.9) 2.21 (1.60-3.8) 2.42 (1.52-4.98) 2.12 (1.45-3.46) 2.4 (1.53-4.5) 
0-2.4 - Normal 202 (54.89) 69 (51.11) 56 (58.33) 215 (52.96) 149 (53.02) 49 (53.26) 72 (57.14) 88 (55.70) 150 (51.02) 67 (57.26) 187 (51.94) 
2.5-4 – Moderately elevated 75 (20.38) 24 (17.78) 15 (15.63) 83 (20.44) 53 (18.86) 21 (22.83) 23 (18.25) 34 (21.52) 55 (18.71) 24 (20.51) 73 (20.28) 
>4 – Severely elevated 91 (24.73) 42 (31.11) 25 (26.04) 108 (26.60) 79 (28.11) 22 (23.91) 31 (24.60) 36 (22.78) 89 (30.27) 26 (22.22) 100 (27.78) 
HAART regimen: 1a  443 (54.96) 176 (53.01) 113 (54.59) 505 (54.30) 339 (54.24) 120 (51.95) 152 (55.88) 186 (52.25) 366 (57.82) 158 (53.56) 425 (56.82) 
   1b  73 (9.06) 34 (10.24) 21 (10.14) 86 (9.25) 60 (9.60) 25 (10.82) 22 (8.09) 39 (10.96) 50 (7.90) 22 (7.46) 77 (10.29) 
   Other  290 (35.98) 122 (36.75) 73 (35.27) 339 (36.45) 226 (36.16) 86 (37.23) 98 (36.03) 131 (36.80) 217 (34.28) 115 (38.98) 246 (32.89) 
Baseline study Pap smear results: Negative    234 (27.30) 87 (25.22) 71 (32.57) 250 (25.43) 183 (27.64) 61 (24.40) 73 (26.07) 104 (27.30) 188 (28.48) 76 (25.00) 210 (27.63) 
                           Moderate  354 (41.31) 120 (34.78) 81 (37.16) 392 (39.88) 244 (36.86) 99 (39.60) 126 (45.00) 162 (42.52) 243 (36.82) 126 (41.45) 299 (39.34) 
                           Severe/ICC  266 (31.04) 137 (39.71) 66 (30.28) 337 (34.28) 233 (35.20) 89 (35.60) 80 (28.57) 114 (29.92) 227 (34.39) 101 (33.22) 248 (32.63) 
                           Unknown  3 (0.35) 1 (0.29) 0 (0) 4 (0.41) 2 (0.30) 1 (0.40) 1 (0.36) 1 (0.26) 2 (0.30) 1 (0.33) 3 (0.39) 
Previous Pap smear results:  Negative 514 (76.15) 9 (69.23) 114 (78.62) 409 (75.32) 289 (75.06) 109 (76.76) 122 (77.71) 297 (77.95) 177 (74.37) 234 (76.97) 238 (75.80) 
                        Moderate  28 (4.15) 1 (7.69) 7 (4.83) 22 (4.05) 14 (3.64) 8 (5.63) 7 (4.46) 14 (3.67) 11 (4.62) 18 (5.92) 10 (3.18) 
                        Severe/ICC 1 (0.15) 0 (0) 1 (0.69) 0 (0) 0 (0) 1 (0.70) 0 (0) 1 (0.26) 0 (0) 0 (0) 1 (0.32) 
                        Unknown  132 (19.56) 3 (23.08) 23 (15.86) 112 (20.63) 82 (21.30) 24 (16.90) 28 (17.83) 69 (18.11) 50 (21.01) 52 (17.11) 65 (20.70) 
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Appendix 2a: Sensitivity analysis of 12 month follow up visit  
A sensitivity analysis was conducted to determine any significant differences between study 
participants that came for their 12 month study visit and those that did not come for their 12 month 
study visit 
Factor 12mo F/U Not done (n=514 ) 
12mo F/U 
Done (n= 688) 
On HAART    
No  19 (3.19) 25 (3.68) 
Yes 484 (96.22) 654 (96.32) 
Age group at HAART initiation     
18-29 114 (23.55) 142 (21.71) 
30-39 247 (51.03) 292 (44.65) 
40-49 106 (21.90) 185 (28.29) 
50+ 17 (3.51) 35 (5.35) 
Baseline CD4     
0-50 88 (22.51) 103 (19.88) 
51-100 81 (20.72) 86 (16.60) 
101-250 183 (46.80) 266 (51.35) 
251-350 18 (4.60) 29 (5.60) 
>350 21 (5.37) 34 (6.56) 
Baseline VL     
<100000 79 (75.24) 125 (77.16) 
>100000 26 (24.76) 37 (22.84) 
HAART regimen at initiation   
1a 244 (50.41) 375 (57.34) 
1b 43 (8.88) 64 (9.79) 
Other 197 (40.70) 215 (32.87)  
Baseline study Pap smear results   
Negative  66 (13.12) 254 (37.08) 
Moderate                                                               127 (25.25) 343 (50.07) 
Severe 308 (61.23) 88 (12.85) 
ICC 2 (0.40) 2 (0.29) 
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Appendix 2b: Sensitivity analysis for disease progression at 12 month 
follow up visit  
A sensitivity analysis was conducted among patients that did not have a 12 month visit (n=514) 
and thus did not have their disease progression assessed, to evaluate whether excluding them had 
any impact on the estimates in the main analysis of disease progression. 
Factor 
Disease Development at 12month Follow up - Sensitivity analysis 
Main Analysis No 12 month visit - No 
Disease Development 
No 12 month visit -  Disease 
Development 
Adjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value 
       
Nationality: South African               ref   ref  ref  
   Non-South African  1.79 (0.73-4.38) 0.206 1.74 (0.69-4.40) 0.240 2.03 (0.98-5.01) 0.333 
Currently Employed:  No  ref   ref  ref  
                     Yes   1.24 (0.77-2.02) 0.378 0.82 (0.61-1.95) 0.183 0.88 (0.59-1.73)  
Occupation: Full-time ref  ref  ref  
                       Part-time 0.90 (0.42-1.93) 0.778 0.94 (0.49-1.79) 0.843 0.89 (0.58-1.63) 0.562 
                       Self-Employed 1.51 (0.34-6.81) 0.590 2.02 (0.49-7.23) 0.323 0.70 (0.36-6.80) 0.479 
Snuff Frequency: <5 per day ref  ref  ref  
            > 5 per day 2.59 (0.30-22.29) 0.387 2.05 (0.49-27.00) 0.196 1.95 (0.61-24.82) 0.299 
Hemoglobin (g/dL): <8g/dL ref  ref  ref  
                ≥8g/dL 0.49 (0.77-2.02) 0.151 0.56 (0.65-2.40) 0.752 0.81 (0.35-1.88) 0.630 
Baseline study Pap smear results: Negative   ref  ref  ref  
                                             Moderate/Severe/ICC                                      0.08 (0.05-0.13) <0.001 0.08 (0.04-0.12) <0.001 0.30 (0.08-0.18) <0.001 
HPV Awareness: Aware ref   ref   ref   
            Not Aware 1.39 (0.55-3.51) 0.487 1.22 (0.61-2.64) 0.563 1.26 (0.76-2.11) 0.372 
Appendix 2c: Log rank test of equality of survival functions  
The log rank tests were conducted to test for equality of survival curves.  
Factor Log rank Chi2 p-value 
Pap smear screening awareness 0.23 0.633 
HPV virus awareness 0.01 0.988 
Perceived Risk of getting cervical cancer disease 0.78 0.678 
Practice according to national cervical cancer guidelines 0.02 0.897 
Practice according to national HIV treatment guidelines 0.02 0.890 
Age group 0.37 0.947 
Race 0.85 0.357 
Nationality 1.40 0.236 
Marital status 1.00 0.910 
Education level 4.46 0.216 
Currently employed 0.88 0.349 
Occupation 2.58 0.275 
Currently smoking 1.48 0.223 
Smoking frequency 0.01 0.600 
Currently taking snuff  2.31 0.128 
Snuff frequency 2.96 0.286 
Alcohol 0.01 0.976 
Baseline WHO staging 0.01 0.972 
Baseline Body mass index (BMI) 0.54 0.764 
Baseline CD4 6.89 0.142 
Baseline HIV VL 1.22 0.269 
Baseline Haemoglobin (Hg) 0.24 0.622 
Baseline Aspartate transaminase (AST) 0.53 0.468 
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Baseline Alanine aminotransferase (ALT) 2.69 0.101 
Baseline Lactate levels 3.85 0.146 
On HAART 2.85 0.650 
HAART  regimen at HAART initiation 2.49 0.288 
Previous Pap screening results 0.23 0.634 
Baseline study Pap screening results 3.01 0.043 
Disease progression 2.45 0.263 
Appendix 2d. Global tests for proportional hazards assumptions  
Global tests for proportional hazards assumptions based on Schoenfeld residuals were conducted 
after fitting univariate Cox models on all covariates. 
Factor P Value Global Test 
for PH Assumption 
Pap smear screening awareness 0.556 
HPV virus awareness 0.108 
Perceived Risk of getting cervical cancer disease 0.750 
Practice according to national cervical cancer guidelines 0.765 
Practice according to national HIV treatment guidelines 0.672 
Age group 0.791 
Race 0.399 
Nationality <0.001 
Marital status 0.355 
Education level 0.789 
Currently employed 0.781 
Occupation 0.970 
Currently smoking 0.974 
Smoking frequency 0.336 
Currently taking snuff  0.834 
Snuff frequency 0.532 
Alcohol 0.200 
Baseline WHO staging 0.261 
Baseline Body mass index (BMI) 0.701 
Baseline CD4 0.659 
Baseline HIV VL 0.465 
Baseline Haemoglobin (Hg) 0.520 
Baseline Aspartate transaminase (AST) 0.367 
Baseline Alanine aminotransferase (ALT) 0.341 
Baseline Lactate levels 0.053 
On HAART 0.402 
HAART  regimen at HAART initiation 0.259 
Previous Pap screening results 0.150 
Baseline study Pap screening results 0.574 
Disease progression 0.972 
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Appendix 3: Ethical clearance certificate 
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Appendix 4: Data gatekeeper letter for permission to use VICAR 1 dataset 
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Appendix 5: Permission letter from Right to Care, the Clinical entity in 
which the patients are based 
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Appendix 6: VICAR 1 study inclusion and exclusion criteria  
D. METHODS 
 
i Study Participants 
A total of 1,200 HIV seropositive women will be recruited in the Themba Lethu Clinic in 
Johannesburg, South Africa.  
 
ii Inclusion Criteria 
Women 18-65 years of age 
Not menstruating (can be screened after menstruation over) 
Able to sign consent 
Able to follow the study protocol 
HIV positive (by 2 different rapid tests, a HIV viral load >5,000, ELISA, Western blot) 
  
iii Exclusion Criteria Pregnant 
Clinically active STD (may participate after adequate treatment)  
Known and previous treatment for HSIL by any method (cryotherapy, LLETZ or cone biopsy) 
Previous Hysterectomy with removal of the cervix 
Significant medical illness/mental illness that the investigator feels would prevent the participant 
from complying with the protocol or place the participant at medical risk  
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Appendix 7: VICAR 1 study questionnaire 
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